# 1,3,4-Oxadiazole Derivatives: Synthesis, Characterization, Antimicrobial Potential, and Computational Studies

Authors: Suman Bala; Sunil Kamboj; Anu Kajal; Vipin Saini; Deo Nanadan Prasad
Journal: BioMed Research International
 (2014)

---

## Abstract

We report the synthesis and biological assessment of 1,3,4-oxadiazole substituted 24 derivatives as novel, potential antibacterial agents. The structures of the newly synthesized derivatives were established by the combined practice of UV, IR,1H NMR, 13C NMR, and mass spectrometry. Further these synthesized derivatives were subjected to antibacterial activity against all the selected microbial strains in comparison with amoxicillin and cefixime. The antibacterial activity of synthesized derivatives was correlated with their physicochemical and structural properties by QSAR analysis using computer assisted multiple regression analysis and four sound predictive models were generated with good R2, Radj2, and Fischer statistic. The derivatives with potent antibacterial activity were subjected to molecular docking studies to investigate the interactions between the active derivatives and amino acid residues existing in the active site of peptide deformylase to assess their antibacterial potential as peptide deformylase inhibitor.


---

## Body

## 1. Introduction

Oxadiazoles are the heterocyclic compounds containing one oxygen and two nitrogen atoms in a five membered ring [1, 2] possessing a diversity of useful biological effects [3]. Oxadiazole is considered to be resultant from furan by replacement of two methane (–CH=) groups by two pyridine type nitrogen atoms (–N=) [2]. Several methods have been reported in the literature for the synthesis of 1,3,4-oxadiazoles. The commonly used synthetic route for 1,3,4-oxadiazoles includes reactions of acid hydrazides (or hydrazine) with acid chlorides/carboxylic acids and direct cyclization of diacylhydrazines using a variety of dehydrating agents such as phosphorous oxychloride [3], thionyl chloride [4], phosphorous pentaoxide [5], triflic anhydride [6], polyphosphoric acid [7], and direct reaction of acid with (N-isocyanimino-) triphenylphosphorane [8–11].Researchers have already reported that gram positive bacteria are much more susceptible to antimicrobial agents as compared to gram negative bacteria [12]. These differences may be attributed to the fact that the cell wall in gram positive bacteria is of single layer whereas the gram negative bacteria have multilayered cell wall. Gram negative bacteria possess an outer membrane and a unique periplasmic space which is not found in gram positive bacteria [13]. The resistance of gram negative bacteria towards antibacterial substances is due to more lipophilic nature of membrane, which acts as a barrier for various antimicrobial compounds. It was expected that hydrophilic compounds are unable to penetrate the cell membranes of these bacteria. Gram positive bacteria do not have such outer membrane and complex cell wall structure. Antibacterial substances can easily destroy the bacterial cell wall and cytoplasmic membrane of gram positive bacteria, which results in leakage of the cytoplasm [14].Peptide deformylase (PDF) is a vital and extremely conserved enzyme, belongs to a subfamily of metalloprotease [15], and has emerged out as a target of efforts to develop novel antibacterial agents [16]. It embraces iron and is responsible for protein maturation by the exclusion of the N-formyl group from the terminal methionine residue through Fe2+ mediated catalysis which leads to inhibition of protein synthesis in bacteria [17].Computational studies are the crucial steps in the drug designing. There are numerous areas of computational studies and one of them is identification of relationships between chemical structures and properties and recognized as QSAR. Quantitative structural activity relationship practices molecular parameters to enumerate a pharmacological or chemical property for a set of molecules [18].Docking study is the computational routine to determine probable binding manners of a ligand to the dynamic site of a receptor. It makes an image of the dynamic site with interaction points known as grid. Then it fits the ligand in the binding site either by grid search or energy search [19].In the present paper, we have explored substituted 1,3,4-oxadiazole derivatives as antibacterial agents with the support of QSAR and molecular docking studies by targeting the enzyme peptide deformylase.


## 2. Chemistry

The substituted aromatic acids were used as a versatile starting material for the synthesis of 1,3,4-oxadiazoles derivatives involving the formation of corresponding esters and hydrazides. Ethyl esters were synthesized from substituted aromatic acids by means of Fischer esterification which were further reacted with hydrazine hydrate in presence of ethanol to get corresponding hydrazide derivative. The hydrazide derivatives then reacted withβ-benzoyl propionic acid in the presence of phosphorus oxychloride (cyclodehydrating agent) to get final compounds6a–h (Figure 1). The chemistry of compounds8a–h was already reported in our previous studies [20]. The substituted aromatic acid hydrazides fromo-benzoyl benzoic acid reacted with aromatic aldehydes under slight acidic conditions to get the substituted hydrazone derivatives which were then cyclized in presence of bromine, acetic acid, and sodium acetate to get 1,3,4-oxadiazole derivatives(13a–h) (Figure 2). Reaction monitoring was done by means of thin layer chromatography (TLC). All the new synthesized compounds were characterized by melting point and spectroscopic analysis (UV-Visible, IR,1H NMR, 13C NMR, and MS).Figure 1
Synthetic scheme of 1-(4-methoxy-phenyl)-3-[5-(substituted phenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6a–h).Figure 2
Synthetic scheme of [2-(5-substituted-phenyl-[1,3,4]oxadiazol-2-yl)-phenyl]phenyl-methanone(13a–h).


## 3. Experimental Section

### 3.1. Material and Method

Reagent and solvents used were obtained from commercial sources. Analytical thin layer chromatography was carried out on TLC plates of3×15cm coated with silica gel G for reaction monitoring and for determination of retardation factor. Spots of TLC were located by iodine chamber. Melting points of newly synthesized derivatives were determined on digital melting point apparatus (Flora; Perfit, India) and were found uncorrected (Table 2). The λmax⁡ was calculated by using double beam UV-Visible 1800 Shimadzu spectrophotometer and the values are given in Table 2. The IR spectra were recorded on FTIR-Shimadzu spectrometer using Nujol method. 1H NMR and 13C NMR spectra were recorded on BRUKER AVANCE II 400 NMR spectrometer operating at 400 MHz and 125 MHz, respectively, using CDCl3, chemical shift values were expressed in δ ppm. For mass spectra, solutions were made in HPLC grade methanol and spectra were obtained with Vg-11-250J70S spectrophotometer at 70 eV using electron ionization (EI source). Chem 3D Ultra (version 10) was employed for structural similarity studies. QSAR studies were performed by multiple linear regression analysis using Analyze-it version 3.0 software. Molegro Virtual Docker 5.0.0. software was employed for the molecular docking studies.


### 3.2. General Procedure for the Synthesis of 1-(4-Methoxy-phenyl)-3-(5-phenyl-1,3,4-oxadiazol-2-yl)propan-1-one(6a–h)

Aryl hydrazide2a (1 M) was dissolved in phosphorous oxychloride (5 mL) and to it compound5 (equimolar; 1 M) was added. The reaction mixture, after refluxing for 6-7 hours, was cooled to room temperature and poured onto crushed ice. On neutralization of the contents with sodium bicarbonate solution (20%), a solid mass separated out. This was filtered and washed with water. It was crystallized by using methanol to give6a. Similarly compounds (6b–h) were prepared (Figure 1) [21, 22]. The corresponding R for6a–h is given in Table 1.Table 1
Substituted groups (R) of different synthesized compounds.
Compound
R
R′
6a
6b
6c
6d
6e
6f
6g
6h
8a
8b
8c
8d
8e
8f
8g
8h
13a
13b
13c
13d
13e
13f
13g
13hTable 2
Physical properties and UV-Visible analysis of synthesized 1,3,4-oxadiazole derivatives.
Compound
Molecular formula
Molecular weight
Solubility
λ
max
⁡
R
f value
6a
C18H16N2O3
308.33
DMSO, MeOH, CHCl3
263
0.54
6b
C18H17N3O3
323.35
DMSO, MeOH, CHCl3
278
0.42
6c
C18H16N2O3
324.33
DMSO, MeOH, CHCl3
265
0.47
6d
C18H16N2O3
324.33
DMSO, MeOH, CHCl3
250
0.68
6e
C18H15ClN2O3
342.78
DMSO, MeOH, CHCl3
266
0.40
6f
C18H15ClN2O3
342.78
DMSO, MeOH, CHCl3
265
0.43
6g
C19H18N2O3
322.36
DMSO, MeOH, CHCl3
254
0.41
6h
C18H15N3O5
353.33
DMSO, MeOH, CHCl3
245
0.35
13a
C21H14N2O2
326.35
DMSO, MeOH, CHCl3
281
0.51
13b
C21H13ClN2O2
360.79
DMSO, MeOH, CHCl3
281
0.58
13c
C21H13N3O4
371.35
DMSO, MeOH, CHCl3
283
0.49
13d
C22H16N2O2
340.37
DMSO, MeOH, CHCl3
281
0.55
13e
C22H16N2O4
372.37
DMSO, MeOH, CHCl3
281
0.61
13f
C21H14N2O3
342.35
DMSO, MeOH, CHCl3
285
0.60
13g
C21H13N3O4
371.35
DMSO, MeOH, CHCl3
285
0.58
13h
C21H14N2O3
342.35
DMSO, MeOH, CHCl3
283
0.67
Mobile phase for TLC: petroleum ether: ethyl acetate : MeOH (6 : 3 : 1).


#### 3.2.1. 1-(4-Methoxy-phenyl)-3-(5-phenyl-1,3,4-oxadiazol-2-yl)propan-1-one(6a)

Yield 89.90%, yellow crystals, mp (°C): 240–242; IR (Nujol, cm−1): 3003.17 (CHarom), 2818 (CHaliph), 1685.79 (C=O), 1595.13 (C=N), 1255.66 (C–O–Casymm), 1166.93 (CH bend), 1018.41 (C–O–Csymm), 931.62, 823.60 (CH bend); 1H NMR (CDCl3, 400 MHz, ppm): 8.1 (d, 2H, H-p-methoxy phenyl (J=7 Hz), 7.9 (d, 2H, H-2,6-phenyl (J=8.1 Hz), 7.6 (d, 3H, H-3,4,5-phenyl (J=7.7 Hz), 7.1 (d, 2H, H-p-methoxy phenyl (J=7.3 Hz), 3.8 (s, 3H, OCH3), 3.1 (t, 2H, CH2 (J=6.4 Hz), 2.9 (t, 2H, CH2 (J=6.1 Hz); 13C NMR (CDCl3); 24.6 (C-6), 41.2 (C-7), 197.2 (C-8), 136.5 (C-10), 127.0 (C-11,15), 129.1 (C-12,14), 128.5 (C-13), 129.7 (C-16), 129.5 (C-17,21), 114.2 (C-18,20), 165.9 (C-19), 56.2 (C-22); MS:m/z 308.12, 309.12 (M + 1), 310.12 (M + 2).


#### 3.2.2. 1-(4-Methoxy-phenyl)-3-[5-(4-aminophenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6b)

Yield 83.0%, light yellow crystals, mp (°C): 242-243; IR (Nujol, cm−1): 3450.65 (NH), 2999.31, 2970.38 (CH), 1703.14 (C=O), 1699.29 (C=N), 1577.77 (NH), 1286.52 (C–O–Casymm), 1165 (CH), 1058.92 (C–O–Csymm), 929.69, 842.69 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 7.99 (d, 2H, H-p-methoxy phenyl (J=8.4 Hz), 7.59 (d, 2H, H-p-amino phenyl (J=8 Hz), 7.09 (d, 2H, H-p-methoxy phenyl (J=7.8 Hz), 6.49 (d, 2H, H-p-amino phenyl (J=7.9 Hz), 3.98 (s, 2H, NH2), 3.79 (s, 3H, OCH3), 3.10 (t, 2H, CH2 (J=6.6 Hz), 2.89 (t, 2H, CH2 (J=6.3 Hz); 13C NMR (CDCl3); 24.6 (C-6), 40.9 (C-7), 197.5 (C-8), 126.5 (C-10), 127.8 (C-11,15), 115.6 (C-12,14), 146.7 (C-13), 129.7 (C-16), 129.6 (C-17,21), 114.0 (C-18,20), 166.2 (C-19), 55.8 (C-23); MS:m/z 323.13, 324.12 (M + 1), 325.15 (M + 2).


#### 3.2.3. 1-(4-Methoxy-phenyl)-3-[5-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6c)

Yield 89.80%, yellow powder, mp (°C): 255.00; IR (Nujol, cm−1): 3653.18 (OH), 3045.60 (CHarom), 2767.85 (CHaliph), 1670.35 (C=O), 1602.85 (C=N), 1543.06 (C=C), 1365.60 (OH), 1282.66 (C–O–Casymm), 1031.92 (C–O–Csymm), 767.67 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 7.9 (d, 2H, H-p-methoxy phenyl (J=7.8 Hz), 7.7 (d, 2H,H-p-hydroxy phenyl (J=7.7 Hz), 7.0 (d, 2H, H-p-methoxy phenyl (J=8.0 Hz), 6.8 (d, 2, H-p-hydroxy phenyl (J=8.0 Hz), 4.9 (s, 1H,OH), 3.7 (s, 3H,OCH3), 3.0 (t, 2H,CH2 (J=6.1 Hz), 2.8 (t, 2H,CH2 (J=6.0 Hz); 13C NMR (CDCl3); 24.7 (C-6), 40.6 (C-7), 197.6 (C-8), 129.1 (C-10), 128.4 (C-11,15), 116.2 (C-12,14), 157.3 (C-13), 129.7 (C-16), 129.6 (C-17,21), 114.0 (C-18,20), 166.5 (C-19), 56.0 (C-23); MS:m/z 324.11, 325.13 (M + 1), 326.12 (M + 2).


#### 3.2.4. 1-(4-Methoxy-phenyl)-3-[5-(2-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6d)

Yield 80.80%, yellow crystals, mp (°C): 253.00; IR (Nujol, cm−1): 3626.33 (OH), 3025.48, 2925.17 (CH), 1698.40 (C=O), 1605.81 (C=N), 1522.87 (C=C), 1363.73 (OH), 1259.57 (C–O–Casymm), 1148.66 (CH), 1013.64 (C–O–Csymm), 895.99, 817.85, 738.77 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 7.9 (d, 2H, H-p-methoxy phenyl (J=8.4 Hz), 7.6 (m, 1H, H-p-hydroxy phenyl (J=7.6 Hz), 7.3 (m, 1H, H-o-hydroxy phenyl (J=7.7 Hz), 7.1 (m, 3H, 2H-p-methoxy phenyl and 1H-o-hydroxy phenyl), 6.9 (m, 1H, H-o-hydroxy phenyl (J=8.1 Hz), 4.4 (s, 1H, OH), 3.8 (s, 3H, OCH3), 3.1 (t, 2H, CH2 (J=6.1 Hz), 2.9 (t, 2H, CH2 (J=6.0 Hz) 13C NMR (CDCl3); 24.4 (C-6), 40.9 (C-7), 197.4 (C-8), 123.7 (C-10), 155.8 (C-11), 116.2 (C-12), 129.9 (C-13), 121.6 (C-14), 128.4 (C-15), 129.6 (C-16), 129.4 (C-17,21), 114.1 (C-18,20), 166.4 (C-19), 56.2 (C-23); MS:m/z 324.11, 325.13 (M + 1), 326.12 (M + 2).


#### 3.2.5. 1-(4-Methoxy-phenyl)-3-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6e)

Yield 78.80%, yellow powder, mp (°C): 270–272; IR (Nujol, cm−1): 3064.89 (CHarom), 2742.76 (CHaliph), 1614.42 (C=O), 1539.29 (C=N), 1292.24 (C–O–Casymm), 1018.41 (C–O–Csymm), 796.53 (CH), 567.07 (C–Cl); 1H NMR (CDCl3, 400 MHz, ppm): 7.9 (d, 2H,p-methoxy phenyl (J=7.68 Hz), 7.7 (d, 2H,p-chloro phenyl (J=7.7 Hz), 7.5 (d, 2H,p-chloro phenyl (J=8.0 Hz), 7.1 (d, 2H,p-methoxy phenyl (J=8.1 Hz), 3.8 (s, 3H, OCH3), 3.2 (t, 2H, CH2 (J=6.1 Hz), 3.0 (t, 2H, CH2 (J=6.0 Hz); 13C NMR (CDCl3); 24.4 (C-6), 40.8 (C-7), 198.0 (C-8), 134.6 (C-10), 128.4 (C-11,15), 129.4 (C-12,14), 133.8 (C-13), 129.7 (C-16), 129.7 (C-17,21), 114.0 (C-18,20), 166.8 (C-19), 56.1 (C-23); MS:m/z 342.08, 344.07 (M + 1), 343.08 (M + 2).


#### 3.2.6. 1-(4-Methoxy-phenyl)-3-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6f)

Yield 78.00%, Yellow powder, mp (°C): 273.0; IR (Nujol, cm−1): 3076.46 (CHarom), 2744.71 (CHaliph), 1618.28 (C=O), 1556.55 (C=N), 1051.20 (C–O–C), 821.68 (CH), 590.22 (C–Cl); 1H NMR (CDCl3, 400 MHz, ppm): 8.0 (d, 2H,H-p-methoxy phenyl (J=8.9 Hz), 7.6 (m, 2H,H-o-chloro phenyl (J=8.1 Hz), 7.4 (m, 1H, H-o-chloro phenyl), 7.2 (m, 1H, H-o-chloro phenyl), 7.1 (d, 2H, H-p-methoxy phenyl (J=8.2 Hz), 3.7 (s, H, OCH3), 3.2 (t, H, CH2 (J=6.3 Hz), 3.0 (t, H, CH2 (J=6.3 Hz); 13C NMR (CDCl3); 24.2 (C-6), 40.4 (C-7), 196.9 (C-8), 137.9 (C-10), 127.4 (C-11), 134.3 (C-12), 128.9 (C-13), 130.4 (C-14), 125.1 (C-15), 128.9 (C-16), 129.5 (C-17,21), 114.0 (C-18,20), 166.9 (C-19), 56.4 (C-23); MS:m/z 342.08, 344.07 (M + 1), 343.08 (M + 2).


#### 3.2.7. 1-(4-Methoxy-phenyl)-3-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6g)

Yield 79.20%, Brown crystals, mp (°C): 250–253; IR (Nujol, cm−1): 3028.24 (CHarom), 2779.42 (CHaliph), 1699.29 (C=O), 1514.12 (C=N), 1301.95 (C–O–Casymm), 1190.08 (C–O–Csymm), 908.47, 819.75, 773.46 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 7.8 (d, 2H, H-p-methoxy phenyl (J=8.4 Hz), 7.5 (d, 2H, H-p-methyl phenyl (J=8.4 Hz), 7.2 (d, 2H, H-p-methyl phenyl (J=8.3 Hz), 7.0 (d, 2H, H-p-methoxy phenyl (J=8.4 Hz), 3.7 (s, 3H, OCH3), 3.1 (t, 2H, CH2), 2.9 (t, 2H, CH2 (J=6.2 Hz), 2.3 (s, 3H, CH3 (J=6.0 Hz); 13C NMR (CDCl3); 24.9 (C-6), 41.2 (C-7), 197.4 (C-8), 133.5 (C-10), 126.6 (C-11,15), 129.3 (C-12,14), 137.7 (C-13), 129.2 (C-16), 129.4 (C-17,21), 20.9 (C-22), 114.2 (C-18,20), 166.5 (C-19), 56.0 (C-23); MS:m/z 322.13, 323.14 (M + 1), 324.11 (M + 2).


#### 3.2.8. 1-(4-Methoxy-phenyl)-3-[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6h)

Yield 90.0%, yellow crystals, mp (°C): 250.00; IR (Nujol, cm−1): 3024.38, 2906 (CH), 1662.64 (C=O), 1631.78 (C=N), 1587.42 (C=C), 1517.98 (N=Oasymm), 1317.38 (N=Osymm), 1064.71 (C–O–C), 939.33, 742 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.4 (d, 2H, H-p-nitro phenyl (J=8.0 Hz), 8.2 (d, 2H, H-p-methoxy phenyl (J=7.7 Hz), 7.8 (d, 2H, H-p-nitro phenyl (J=7.8 Hz), 7.0 (d, 2H, H-p-methoxy phenyl (J=7.6 Hz), 3.7 (s, 3H, OCH3), 3.1 (t, 2H, CH2 (J=6.3 Hz), 2.9 (t, 2H, CH2 (J=6.3 Hz); 13C NMR (CDCl3); 24.4 (C-6), 40.9 (C-7), 197.6 (C-8), 142.6 (C-10), 127.9 (C-11,15), 124.1 (C-12,14), 148.4 (C-13), 129.7 (C-16), 129.6 (C-17,21), 114.0 (C-18,20), 166.4 (C-19), 56.0 (C-23); MS:m/z 353.10, 354.11 (M + 1), 355.11 (M + 2).


### 3.3. General Procedures for the Synthesis of [2-(5-Substituted-phenyl-[1,3,4]oxadiazol-2-yl)-phenyl]-phenyl-methanone(13a–h)

A mixture of12a (0.01 M), anhydrous sodium acetate (0.02 M), and glacial acetic acid was placed in round bottomed flask equipped with separating funnel for the addition of bromine. Bromine (0.8 mL in 5 mL of glacial acetic acid) was added slowly to it while stirring magnetically. After 2 hours of stirring the solution was poured on crushed ice. The resulting solid was separated, dried, and recrystallized from ethyl alcohol. Similarly compounds (13b–h) were prepared (Figure 2) [23]. The corresponding R for13a–h is given in Table 1.


#### 3.3.1. {2-[5-(4-Phenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13a)

Yield 72.45%, white crystals, mp (°C): 291.00; IR (Nujol, cm−1): 3030.17 (CH), 1627.92 (C=O), 1600.92 (C=N), 1519.91 (C=C), 1219.09 (C–O–Casymm), 1043.49 (C–O–Csymm), 920.05, 779.24, 738.74 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.3 (d, 1H, H-diphenyl methanone (J=8.4 Hz), 7.9 (d, 2H, H-phenyl (J=7.7 Hz), 7.7 (m, 3H, H-diphenyl methanone (J=7.7 Hz), 7.6 (m, 1H, H-diphenyl methanone), 7.5 (m, 5H, 2H-diphenyl methanone and 3H-phenyl), 7.3 (m, 2H, diphenyl methanone); 13C NMR (CDCl3): 136.2 (C-6), 128.6 (C-7), 138.3 (C8), 130.1 (C-9), 128.7 (C-10), 130.7 (C-11), 136.5 (C-12), 127.0 (C-13,17), 129.0 (C-14,16), 128.5 (C-15), 187.0 (C-18), 137.8 (C-20), 130.1 (C-21,25), 128.2 (C-22,24), 132.2 (C-23); MS:m/z 326.14, 326.11 (M + 1), 327.11 (M + 2).


#### 3.3.2. {2-[5-(4-Chlorophenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13b)

Yield 76.60%, yellow powder, mp (°C): 283–285; IR (Nujol, cm−1): 3034.03, 2918.30 (CH), 1683.86 (C=O), 1583.56 (C=N), 1521.84 (C=C), 1257.59 (C–O–Casymm), 1176.58 (CH), 1058.92 (C–O–Csymm), 925.83, 811.78, 756.10 (CH), 545.85 (C–Cl); 1H NMR (CDCl3, 400 MHz, ppm): 8.2 (d, 1H, H-diphenyl methanone) (J=7.8 Hz), 7.8 (m, 3H,H-diphenyl methanone and 2H-p-chlorophenyl), 7.6 (m, 3H,H-diphenyl methanone), 7.4 (m, 2H, diphenyl methanone (J=7.8 Hz), 7.2 (d, 4H, 2H-diphenyl methanone and 2H-p-chlorophenyl); 13C NMR (CDCl3): 136.4 (C-6), 128.5 (C-7), 138.7 (C-8), 130.5 (C-9), 128.2 (C-10), 130.9 (C-11), 134.6 (C-12), 128.4 (C-13,17), 129.4 (C-14,16), 133.8 (C-15), 187.2 (C-18), 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 360.07, 362.06 (M + 1), 363.10 (M + 2).


#### 3.3.3. {2-[5-(4-Nitrophenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13c)

Yield 75.50%, brown crystals, mp (°C): 261–263; IR (Nujol, cm−1): 3115.04, 2920.23 (CH), 1651.07 (C=O), 1620.21 (C=N), 1571.99 (C=C), 1496.76 (N=Oasymm), 1365.60 (N=Osymm), 1209.37 (C–O–Casymm), 1120.64 (CH), 1047.35 (N=Osymm), 798.53 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.6 (d, 2H, H-p-nitrophenyl (J=7.7 Hz), 8.3 (m, 3H, 1H-diphenyl methanone and 2H-p-nitrophenyl), 7.9 (m, 3H, 1H-diphenyl methanone (J=8.0 Hz), 7.7 (m, 3H, 1H-diphenyl methanone (J=7.7 Hz), 7.4 (m, 2H, 1H-diphenyl methanone (J=7.9 Hz); 13C NMR (CDCl3): 136.0 (C-6), 128.2 (C-7), 138.3 (C-8), 130.9 (C-9), 128.0 (C-10), 130.4 (C-11), 142.6 (C-12), 127.9 (C-13,17), 124.1 (C-14,16), 148.4 (C-15), 186.9 (C-18), 137.9 (C-21), 128.2 (C-22,26), 127.2 (C-23,25), 129.9 (C-24); MS:m/z 371.09, 372.06 (M + 1), 373.10 (M + 2).


#### 3.3.4. {2-[5-(4-Methylphenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13d)

Yield 75.50%, yellow powder, mp (°C): 257–259; IR (Nujol, cm−1): 3000 (CH), 1655.96 (C=O), 1563.337 (C=N), 1521.90 (C=C), 1236.42 (C–O–Casymm), 1111.05 (CH), 1041.61 (C–O–Csymm), 858.36, 820.75 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.5 (d, 1H, 1H-diphenyl methanone (J=7.8 Hz), 8.0 (d, 2H,p-methyl phenyl (J=8.0 Hz), 7.8 (m, 3H, diphenyl methanone (J=8.0 Hz), 7.6 (m, 3H, diphenyl methanone (J=7.9 Hz), 7.5 (m, 2H, diphenyl methanone (J=7.6 Hz), 7.1 (d, 2H,p-methyl phenyl (J=7.7 Hz), 2.4 (s, 3H, CH3); 13C NMR (CDCl3): 136.9 (C-6), 128.2 (C-7), 138.7 (C-8), 130.5 (C-9), 128.2 (C-10), 130.9 (C-11), 133.5 (C-12), 126.9 (C-13,17), 129.7 (C-14,16), 137.7 (C-15), 187.2 (C-18), 20.9 (C-20), 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 340.10, 341.12 (M + 1), 342.11 (M + 2).


#### 3.3.5. {2-[5-(3-Methoxy-4-hydroxyphenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13e)

Yield 78.80%, yellow powder, mp (°C): 268–271; IR (Nujol, cm−1): 3605.11 (OH), 3073.70, 3032.23 (CH), 1662.71 (C=O), 1558.55 (C=N), 1510.33 (C=C), 1310.69 (OH), 1254.75 (C–O–C), 1117.80 (CH), 983.74, 835.21 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.4 (d, 1H, H-diphenyl methanone (J=7.9 Hz), 7.9 (m, 3H, H-diphenyl methanone (J=7.6 Hz), 7.75 (m, 3H, H-diphenyl methanone (J=7.7 Hz), 7.4 (m, 3H, 1H-p-hydroxy-3-methoxyphenyl and 2H-diphenyl methanone), 7.2 (s, 1H, 1H-p-hydroxy-3-methoxyphenyl), 6.9 (d, 1H, 1H-p-hydroxy-3-methoxypheny l (J=7.5 Hz), 5.5 (s, 1H,OH), 3.7 (s, 3H,OCH3); 13C NMR (CDCl3): 130.1 (C-6), 114.0 (C-7), 149.7 (C-8), 142.9 (C-9), 117.2 (C-10), 120.7 (C-11), 136.8 (C-12), 127.9 (C-13), 138.0 (C-14), 129.4 (C-15), 128.4 (C-16), 130.1 (C-17), 56.3 (C-18), 188.1 (C-20), 137.8 (C-21), 129.9 (C-23,27), 128.5 (C-24,26), 131.9 (C-25); MS:m/z 372.11, 373.13 (M + 1), 374.12 (M + 2).


#### 3.3.6. {2-[5-(4-Hydroxyphenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13f)

Yield 80.0%, light yellow powder, mp (°C): 294-295; IR (Nujol, cm−1): 3624.25 (OH), 3024.38 (CH), 1667.14 (C=O), 1589.34 (C=N), 1554.63 (C=C), 1402.25 (OH), 1247.94 (C–O–C), 1126.43 (CH), 933.70, 862.18, 769.60 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.3 (d, 1H, H-diphenyl methanone (J=8.1 Hz), 7.9 (m, 5H, 2H-4-hydroxy phenyl, 3H-diphenyl methanone), 7.6 (m, 3H, H-diphenyl methanone (J=7.8 Hz), 7.39 (m, 2H, H-diphenyl methanone (J=7.8 Hz), 7.3 (m, 2H, H-diphenyl methanone (J=8.1 Hz), 6.9 (d, 2H,H-p-hydroxy phenyl (J=7.8 Hz), 5.09 (s, 1H,OH); 13C NMR (CDCl3): 136.9 (C-6), 128.2 (C-7), 138.7 (C-8), 130.5 (C-9), 128.2 (C-10), 130.9 (C-11), 129.1 (C-12), 128.4 (C-13,17), 116.2 (C-14,16), 157.3 (C-15), 187.2 (C-18), 20.9 (C-20) 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 342.10, 343.18 (M + 1), 344.11 (M + 2).


#### 3.3.7. {2-[5-(2-Nitrophenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13g)

Yield 75.85%, yellow crystals, mp (°C): 237–239; IR (Nujol, cm−1): 2920.35 (CH), 1668.50 (C=O), 1522.87 (C=N), 1518.04 (C=C), 1511.29 (N=Oasymm), 1371.45 (N=Osymm), 1265.36 (C–O–C), 1160.23, 1108.15, 1098.51 (CH), 758.06 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.3 (d, 1H, H-diphenyl methanone (J=8.2 Hz), 8.0 (m, 2H,o-nitrophenyl (J=7.7 Hz), 7.7 (m, 4H, 1H-o-nitrophenyl and 3H-diphenyl methanone), 7.5 (m, 2H, 1H-o-nitrophenyl and 1H-diphenyl methanone), 7.4 (m, 4H, H-diphenyl methanone (J=7.8 Hz); 13C NMR (CDCl3): 131.6 (C-6), 146.9 (C-7), 124.1 (C-8), 129.4 (C-9), 135.1 (C-10), 127.9 (C-11), 135.9 (C-12), 127.9 (C-13), 138.0 (C-14), 129.4 (C-15), 128.4 (C-16), 130.1 (C-17), 187.0 (C-19), 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 371.10, 372.09 (M + 1), 373.10 (M + 2).


#### 3.3.8. {2-[5-(2-Hydroxyphenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13h)

Yield 78.0%, yellow crystals, mp (°C): 254-255; IR (Nujol, cm−1): 3381.21 (OH), 2987.74 (CH), 1602.85 (C=O), 1591.27 (C=N), 1352.10 (OH), 1070.49 (C–O–C), 742.59 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.5 (s, 1H, OH), 8.39 (d, 1H, H-diphenyl methanone (J=8.5 Hz), 7.81 (m, 3H, H-diphenyl methanone (J=7.5 Hz), 7.61 (m, 5H, H-diphenyl methanone ando-hydroxy phenyl), 7.3 (m, 1H, H-diphenyl methanone (J=8.2 Hz), 6.8 (m, 1H,o-hydroxy phenyl (J=7.7 Hz), 6.7 (m, 1H,o-hydroxy phenyl (J=7.6 Hz), 6.5 (m, 1H,o-hydroxy phenyl (J=7.7 Hz); 13C NMR (CDCl3): 123.7 (C-6), 155.8 (C-7), 116.2 (C-8), 129.9 (C-9), 121.6 (C-10), 128.4 (C-11), 135.9 (C-12), 127.9 (C-13), 138.0 (C-14), 129.4 (C-15), 128.4 (C-16), 130.1 (C-17), 187.0 (C-19), 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 342.10, 343.12 (M + 1), 344.11 (M + 2).


## 3.1. Material and Method

Reagent and solvents used were obtained from commercial sources. Analytical thin layer chromatography was carried out on TLC plates of3×15cm coated with silica gel G for reaction monitoring and for determination of retardation factor. Spots of TLC were located by iodine chamber. Melting points of newly synthesized derivatives were determined on digital melting point apparatus (Flora; Perfit, India) and were found uncorrected (Table 2). The λmax⁡ was calculated by using double beam UV-Visible 1800 Shimadzu spectrophotometer and the values are given in Table 2. The IR spectra were recorded on FTIR-Shimadzu spectrometer using Nujol method. 1H NMR and 13C NMR spectra were recorded on BRUKER AVANCE II 400 NMR spectrometer operating at 400 MHz and 125 MHz, respectively, using CDCl3, chemical shift values were expressed in δ ppm. For mass spectra, solutions were made in HPLC grade methanol and spectra were obtained with Vg-11-250J70S spectrophotometer at 70 eV using electron ionization (EI source). Chem 3D Ultra (version 10) was employed for structural similarity studies. QSAR studies were performed by multiple linear regression analysis using Analyze-it version 3.0 software. Molegro Virtual Docker 5.0.0. software was employed for the molecular docking studies.


## 3.2. General Procedure for the Synthesis of 1-(4-Methoxy-phenyl)-3-(5-phenyl-1,3,4-oxadiazol-2-yl)propan-1-one(6a–h)

Aryl hydrazide2a (1 M) was dissolved in phosphorous oxychloride (5 mL) and to it compound5 (equimolar; 1 M) was added. The reaction mixture, after refluxing for 6-7 hours, was cooled to room temperature and poured onto crushed ice. On neutralization of the contents with sodium bicarbonate solution (20%), a solid mass separated out. This was filtered and washed with water. It was crystallized by using methanol to give6a. Similarly compounds (6b–h) were prepared (Figure 1) [21, 22]. The corresponding R for6a–h is given in Table 1.Table 1
Substituted groups (R) of different synthesized compounds.
Compound
R
R′
6a
6b
6c
6d
6e
6f
6g
6h
8a
8b
8c
8d
8e
8f
8g
8h
13a
13b
13c
13d
13e
13f
13g
13hTable 2
Physical properties and UV-Visible analysis of synthesized 1,3,4-oxadiazole derivatives.
Compound
Molecular formula
Molecular weight
Solubility
λ
max
⁡
R
f value
6a
C18H16N2O3
308.33
DMSO, MeOH, CHCl3
263
0.54
6b
C18H17N3O3
323.35
DMSO, MeOH, CHCl3
278
0.42
6c
C18H16N2O3
324.33
DMSO, MeOH, CHCl3
265
0.47
6d
C18H16N2O3
324.33
DMSO, MeOH, CHCl3
250
0.68
6e
C18H15ClN2O3
342.78
DMSO, MeOH, CHCl3
266
0.40
6f
C18H15ClN2O3
342.78
DMSO, MeOH, CHCl3
265
0.43
6g
C19H18N2O3
322.36
DMSO, MeOH, CHCl3
254
0.41
6h
C18H15N3O5
353.33
DMSO, MeOH, CHCl3
245
0.35
13a
C21H14N2O2
326.35
DMSO, MeOH, CHCl3
281
0.51
13b
C21H13ClN2O2
360.79
DMSO, MeOH, CHCl3
281
0.58
13c
C21H13N3O4
371.35
DMSO, MeOH, CHCl3
283
0.49
13d
C22H16N2O2
340.37
DMSO, MeOH, CHCl3
281
0.55
13e
C22H16N2O4
372.37
DMSO, MeOH, CHCl3
281
0.61
13f
C21H14N2O3
342.35
DMSO, MeOH, CHCl3
285
0.60
13g
C21H13N3O4
371.35
DMSO, MeOH, CHCl3
285
0.58
13h
C21H14N2O3
342.35
DMSO, MeOH, CHCl3
283
0.67
Mobile phase for TLC: petroleum ether: ethyl acetate : MeOH (6 : 3 : 1).


### 3.2.1. 1-(4-Methoxy-phenyl)-3-(5-phenyl-1,3,4-oxadiazol-2-yl)propan-1-one(6a)

Yield 89.90%, yellow crystals, mp (°C): 240–242; IR (Nujol, cm−1): 3003.17 (CHarom), 2818 (CHaliph), 1685.79 (C=O), 1595.13 (C=N), 1255.66 (C–O–Casymm), 1166.93 (CH bend), 1018.41 (C–O–Csymm), 931.62, 823.60 (CH bend); 1H NMR (CDCl3, 400 MHz, ppm): 8.1 (d, 2H, H-p-methoxy phenyl (J=7 Hz), 7.9 (d, 2H, H-2,6-phenyl (J=8.1 Hz), 7.6 (d, 3H, H-3,4,5-phenyl (J=7.7 Hz), 7.1 (d, 2H, H-p-methoxy phenyl (J=7.3 Hz), 3.8 (s, 3H, OCH3), 3.1 (t, 2H, CH2 (J=6.4 Hz), 2.9 (t, 2H, CH2 (J=6.1 Hz); 13C NMR (CDCl3); 24.6 (C-6), 41.2 (C-7), 197.2 (C-8), 136.5 (C-10), 127.0 (C-11,15), 129.1 (C-12,14), 128.5 (C-13), 129.7 (C-16), 129.5 (C-17,21), 114.2 (C-18,20), 165.9 (C-19), 56.2 (C-22); MS:m/z 308.12, 309.12 (M + 1), 310.12 (M + 2).


### 3.2.2. 1-(4-Methoxy-phenyl)-3-[5-(4-aminophenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6b)

Yield 83.0%, light yellow crystals, mp (°C): 242-243; IR (Nujol, cm−1): 3450.65 (NH), 2999.31, 2970.38 (CH), 1703.14 (C=O), 1699.29 (C=N), 1577.77 (NH), 1286.52 (C–O–Casymm), 1165 (CH), 1058.92 (C–O–Csymm), 929.69, 842.69 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 7.99 (d, 2H, H-p-methoxy phenyl (J=8.4 Hz), 7.59 (d, 2H, H-p-amino phenyl (J=8 Hz), 7.09 (d, 2H, H-p-methoxy phenyl (J=7.8 Hz), 6.49 (d, 2H, H-p-amino phenyl (J=7.9 Hz), 3.98 (s, 2H, NH2), 3.79 (s, 3H, OCH3), 3.10 (t, 2H, CH2 (J=6.6 Hz), 2.89 (t, 2H, CH2 (J=6.3 Hz); 13C NMR (CDCl3); 24.6 (C-6), 40.9 (C-7), 197.5 (C-8), 126.5 (C-10), 127.8 (C-11,15), 115.6 (C-12,14), 146.7 (C-13), 129.7 (C-16), 129.6 (C-17,21), 114.0 (C-18,20), 166.2 (C-19), 55.8 (C-23); MS:m/z 323.13, 324.12 (M + 1), 325.15 (M + 2).


### 3.2.3. 1-(4-Methoxy-phenyl)-3-[5-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6c)

Yield 89.80%, yellow powder, mp (°C): 255.00; IR (Nujol, cm−1): 3653.18 (OH), 3045.60 (CHarom), 2767.85 (CHaliph), 1670.35 (C=O), 1602.85 (C=N), 1543.06 (C=C), 1365.60 (OH), 1282.66 (C–O–Casymm), 1031.92 (C–O–Csymm), 767.67 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 7.9 (d, 2H, H-p-methoxy phenyl (J=7.8 Hz), 7.7 (d, 2H,H-p-hydroxy phenyl (J=7.7 Hz), 7.0 (d, 2H, H-p-methoxy phenyl (J=8.0 Hz), 6.8 (d, 2, H-p-hydroxy phenyl (J=8.0 Hz), 4.9 (s, 1H,OH), 3.7 (s, 3H,OCH3), 3.0 (t, 2H,CH2 (J=6.1 Hz), 2.8 (t, 2H,CH2 (J=6.0 Hz); 13C NMR (CDCl3); 24.7 (C-6), 40.6 (C-7), 197.6 (C-8), 129.1 (C-10), 128.4 (C-11,15), 116.2 (C-12,14), 157.3 (C-13), 129.7 (C-16), 129.6 (C-17,21), 114.0 (C-18,20), 166.5 (C-19), 56.0 (C-23); MS:m/z 324.11, 325.13 (M + 1), 326.12 (M + 2).


### 3.2.4. 1-(4-Methoxy-phenyl)-3-[5-(2-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6d)

Yield 80.80%, yellow crystals, mp (°C): 253.00; IR (Nujol, cm−1): 3626.33 (OH), 3025.48, 2925.17 (CH), 1698.40 (C=O), 1605.81 (C=N), 1522.87 (C=C), 1363.73 (OH), 1259.57 (C–O–Casymm), 1148.66 (CH), 1013.64 (C–O–Csymm), 895.99, 817.85, 738.77 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 7.9 (d, 2H, H-p-methoxy phenyl (J=8.4 Hz), 7.6 (m, 1H, H-p-hydroxy phenyl (J=7.6 Hz), 7.3 (m, 1H, H-o-hydroxy phenyl (J=7.7 Hz), 7.1 (m, 3H, 2H-p-methoxy phenyl and 1H-o-hydroxy phenyl), 6.9 (m, 1H, H-o-hydroxy phenyl (J=8.1 Hz), 4.4 (s, 1H, OH), 3.8 (s, 3H, OCH3), 3.1 (t, 2H, CH2 (J=6.1 Hz), 2.9 (t, 2H, CH2 (J=6.0 Hz) 13C NMR (CDCl3); 24.4 (C-6), 40.9 (C-7), 197.4 (C-8), 123.7 (C-10), 155.8 (C-11), 116.2 (C-12), 129.9 (C-13), 121.6 (C-14), 128.4 (C-15), 129.6 (C-16), 129.4 (C-17,21), 114.1 (C-18,20), 166.4 (C-19), 56.2 (C-23); MS:m/z 324.11, 325.13 (M + 1), 326.12 (M + 2).


### 3.2.5. 1-(4-Methoxy-phenyl)-3-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6e)

Yield 78.80%, yellow powder, mp (°C): 270–272; IR (Nujol, cm−1): 3064.89 (CHarom), 2742.76 (CHaliph), 1614.42 (C=O), 1539.29 (C=N), 1292.24 (C–O–Casymm), 1018.41 (C–O–Csymm), 796.53 (CH), 567.07 (C–Cl); 1H NMR (CDCl3, 400 MHz, ppm): 7.9 (d, 2H,p-methoxy phenyl (J=7.68 Hz), 7.7 (d, 2H,p-chloro phenyl (J=7.7 Hz), 7.5 (d, 2H,p-chloro phenyl (J=8.0 Hz), 7.1 (d, 2H,p-methoxy phenyl (J=8.1 Hz), 3.8 (s, 3H, OCH3), 3.2 (t, 2H, CH2 (J=6.1 Hz), 3.0 (t, 2H, CH2 (J=6.0 Hz); 13C NMR (CDCl3); 24.4 (C-6), 40.8 (C-7), 198.0 (C-8), 134.6 (C-10), 128.4 (C-11,15), 129.4 (C-12,14), 133.8 (C-13), 129.7 (C-16), 129.7 (C-17,21), 114.0 (C-18,20), 166.8 (C-19), 56.1 (C-23); MS:m/z 342.08, 344.07 (M + 1), 343.08 (M + 2).


### 3.2.6. 1-(4-Methoxy-phenyl)-3-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6f)

Yield 78.00%, Yellow powder, mp (°C): 273.0; IR (Nujol, cm−1): 3076.46 (CHarom), 2744.71 (CHaliph), 1618.28 (C=O), 1556.55 (C=N), 1051.20 (C–O–C), 821.68 (CH), 590.22 (C–Cl); 1H NMR (CDCl3, 400 MHz, ppm): 8.0 (d, 2H,H-p-methoxy phenyl (J=8.9 Hz), 7.6 (m, 2H,H-o-chloro phenyl (J=8.1 Hz), 7.4 (m, 1H, H-o-chloro phenyl), 7.2 (m, 1H, H-o-chloro phenyl), 7.1 (d, 2H, H-p-methoxy phenyl (J=8.2 Hz), 3.7 (s, H, OCH3), 3.2 (t, H, CH2 (J=6.3 Hz), 3.0 (t, H, CH2 (J=6.3 Hz); 13C NMR (CDCl3); 24.2 (C-6), 40.4 (C-7), 196.9 (C-8), 137.9 (C-10), 127.4 (C-11), 134.3 (C-12), 128.9 (C-13), 130.4 (C-14), 125.1 (C-15), 128.9 (C-16), 129.5 (C-17,21), 114.0 (C-18,20), 166.9 (C-19), 56.4 (C-23); MS:m/z 342.08, 344.07 (M + 1), 343.08 (M + 2).


### 3.2.7. 1-(4-Methoxy-phenyl)-3-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6g)

Yield 79.20%, Brown crystals, mp (°C): 250–253; IR (Nujol, cm−1): 3028.24 (CHarom), 2779.42 (CHaliph), 1699.29 (C=O), 1514.12 (C=N), 1301.95 (C–O–Casymm), 1190.08 (C–O–Csymm), 908.47, 819.75, 773.46 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 7.8 (d, 2H, H-p-methoxy phenyl (J=8.4 Hz), 7.5 (d, 2H, H-p-methyl phenyl (J=8.4 Hz), 7.2 (d, 2H, H-p-methyl phenyl (J=8.3 Hz), 7.0 (d, 2H, H-p-methoxy phenyl (J=8.4 Hz), 3.7 (s, 3H, OCH3), 3.1 (t, 2H, CH2), 2.9 (t, 2H, CH2 (J=6.2 Hz), 2.3 (s, 3H, CH3 (J=6.0 Hz); 13C NMR (CDCl3); 24.9 (C-6), 41.2 (C-7), 197.4 (C-8), 133.5 (C-10), 126.6 (C-11,15), 129.3 (C-12,14), 137.7 (C-13), 129.2 (C-16), 129.4 (C-17,21), 20.9 (C-22), 114.2 (C-18,20), 166.5 (C-19), 56.0 (C-23); MS:m/z 322.13, 323.14 (M + 1), 324.11 (M + 2).


### 3.2.8. 1-(4-Methoxy-phenyl)-3-[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6h)

Yield 90.0%, yellow crystals, mp (°C): 250.00; IR (Nujol, cm−1): 3024.38, 2906 (CH), 1662.64 (C=O), 1631.78 (C=N), 1587.42 (C=C), 1517.98 (N=Oasymm), 1317.38 (N=Osymm), 1064.71 (C–O–C), 939.33, 742 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.4 (d, 2H, H-p-nitro phenyl (J=8.0 Hz), 8.2 (d, 2H, H-p-methoxy phenyl (J=7.7 Hz), 7.8 (d, 2H, H-p-nitro phenyl (J=7.8 Hz), 7.0 (d, 2H, H-p-methoxy phenyl (J=7.6 Hz), 3.7 (s, 3H, OCH3), 3.1 (t, 2H, CH2 (J=6.3 Hz), 2.9 (t, 2H, CH2 (J=6.3 Hz); 13C NMR (CDCl3); 24.4 (C-6), 40.9 (C-7), 197.6 (C-8), 142.6 (C-10), 127.9 (C-11,15), 124.1 (C-12,14), 148.4 (C-13), 129.7 (C-16), 129.6 (C-17,21), 114.0 (C-18,20), 166.4 (C-19), 56.0 (C-23); MS:m/z 353.10, 354.11 (M + 1), 355.11 (M + 2).


## 3.2.1. 1-(4-Methoxy-phenyl)-3-(5-phenyl-1,3,4-oxadiazol-2-yl)propan-1-one(6a)

Yield 89.90%, yellow crystals, mp (°C): 240–242; IR (Nujol, cm−1): 3003.17 (CHarom), 2818 (CHaliph), 1685.79 (C=O), 1595.13 (C=N), 1255.66 (C–O–Casymm), 1166.93 (CH bend), 1018.41 (C–O–Csymm), 931.62, 823.60 (CH bend); 1H NMR (CDCl3, 400 MHz, ppm): 8.1 (d, 2H, H-p-methoxy phenyl (J=7 Hz), 7.9 (d, 2H, H-2,6-phenyl (J=8.1 Hz), 7.6 (d, 3H, H-3,4,5-phenyl (J=7.7 Hz), 7.1 (d, 2H, H-p-methoxy phenyl (J=7.3 Hz), 3.8 (s, 3H, OCH3), 3.1 (t, 2H, CH2 (J=6.4 Hz), 2.9 (t, 2H, CH2 (J=6.1 Hz); 13C NMR (CDCl3); 24.6 (C-6), 41.2 (C-7), 197.2 (C-8), 136.5 (C-10), 127.0 (C-11,15), 129.1 (C-12,14), 128.5 (C-13), 129.7 (C-16), 129.5 (C-17,21), 114.2 (C-18,20), 165.9 (C-19), 56.2 (C-22); MS:m/z 308.12, 309.12 (M + 1), 310.12 (M + 2).


## 3.2.2. 1-(4-Methoxy-phenyl)-3-[5-(4-aminophenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6b)

Yield 83.0%, light yellow crystals, mp (°C): 242-243; IR (Nujol, cm−1): 3450.65 (NH), 2999.31, 2970.38 (CH), 1703.14 (C=O), 1699.29 (C=N), 1577.77 (NH), 1286.52 (C–O–Casymm), 1165 (CH), 1058.92 (C–O–Csymm), 929.69, 842.69 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 7.99 (d, 2H, H-p-methoxy phenyl (J=8.4 Hz), 7.59 (d, 2H, H-p-amino phenyl (J=8 Hz), 7.09 (d, 2H, H-p-methoxy phenyl (J=7.8 Hz), 6.49 (d, 2H, H-p-amino phenyl (J=7.9 Hz), 3.98 (s, 2H, NH2), 3.79 (s, 3H, OCH3), 3.10 (t, 2H, CH2 (J=6.6 Hz), 2.89 (t, 2H, CH2 (J=6.3 Hz); 13C NMR (CDCl3); 24.6 (C-6), 40.9 (C-7), 197.5 (C-8), 126.5 (C-10), 127.8 (C-11,15), 115.6 (C-12,14), 146.7 (C-13), 129.7 (C-16), 129.6 (C-17,21), 114.0 (C-18,20), 166.2 (C-19), 55.8 (C-23); MS:m/z 323.13, 324.12 (M + 1), 325.15 (M + 2).


## 3.2.3. 1-(4-Methoxy-phenyl)-3-[5-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6c)

Yield 89.80%, yellow powder, mp (°C): 255.00; IR (Nujol, cm−1): 3653.18 (OH), 3045.60 (CHarom), 2767.85 (CHaliph), 1670.35 (C=O), 1602.85 (C=N), 1543.06 (C=C), 1365.60 (OH), 1282.66 (C–O–Casymm), 1031.92 (C–O–Csymm), 767.67 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 7.9 (d, 2H, H-p-methoxy phenyl (J=7.8 Hz), 7.7 (d, 2H,H-p-hydroxy phenyl (J=7.7 Hz), 7.0 (d, 2H, H-p-methoxy phenyl (J=8.0 Hz), 6.8 (d, 2, H-p-hydroxy phenyl (J=8.0 Hz), 4.9 (s, 1H,OH), 3.7 (s, 3H,OCH3), 3.0 (t, 2H,CH2 (J=6.1 Hz), 2.8 (t, 2H,CH2 (J=6.0 Hz); 13C NMR (CDCl3); 24.7 (C-6), 40.6 (C-7), 197.6 (C-8), 129.1 (C-10), 128.4 (C-11,15), 116.2 (C-12,14), 157.3 (C-13), 129.7 (C-16), 129.6 (C-17,21), 114.0 (C-18,20), 166.5 (C-19), 56.0 (C-23); MS:m/z 324.11, 325.13 (M + 1), 326.12 (M + 2).


## 3.2.4. 1-(4-Methoxy-phenyl)-3-[5-(2-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6d)

Yield 80.80%, yellow crystals, mp (°C): 253.00; IR (Nujol, cm−1): 3626.33 (OH), 3025.48, 2925.17 (CH), 1698.40 (C=O), 1605.81 (C=N), 1522.87 (C=C), 1363.73 (OH), 1259.57 (C–O–Casymm), 1148.66 (CH), 1013.64 (C–O–Csymm), 895.99, 817.85, 738.77 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 7.9 (d, 2H, H-p-methoxy phenyl (J=8.4 Hz), 7.6 (m, 1H, H-p-hydroxy phenyl (J=7.6 Hz), 7.3 (m, 1H, H-o-hydroxy phenyl (J=7.7 Hz), 7.1 (m, 3H, 2H-p-methoxy phenyl and 1H-o-hydroxy phenyl), 6.9 (m, 1H, H-o-hydroxy phenyl (J=8.1 Hz), 4.4 (s, 1H, OH), 3.8 (s, 3H, OCH3), 3.1 (t, 2H, CH2 (J=6.1 Hz), 2.9 (t, 2H, CH2 (J=6.0 Hz) 13C NMR (CDCl3); 24.4 (C-6), 40.9 (C-7), 197.4 (C-8), 123.7 (C-10), 155.8 (C-11), 116.2 (C-12), 129.9 (C-13), 121.6 (C-14), 128.4 (C-15), 129.6 (C-16), 129.4 (C-17,21), 114.1 (C-18,20), 166.4 (C-19), 56.2 (C-23); MS:m/z 324.11, 325.13 (M + 1), 326.12 (M + 2).


## 3.2.5. 1-(4-Methoxy-phenyl)-3-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6e)

Yield 78.80%, yellow powder, mp (°C): 270–272; IR (Nujol, cm−1): 3064.89 (CHarom), 2742.76 (CHaliph), 1614.42 (C=O), 1539.29 (C=N), 1292.24 (C–O–Casymm), 1018.41 (C–O–Csymm), 796.53 (CH), 567.07 (C–Cl); 1H NMR (CDCl3, 400 MHz, ppm): 7.9 (d, 2H,p-methoxy phenyl (J=7.68 Hz), 7.7 (d, 2H,p-chloro phenyl (J=7.7 Hz), 7.5 (d, 2H,p-chloro phenyl (J=8.0 Hz), 7.1 (d, 2H,p-methoxy phenyl (J=8.1 Hz), 3.8 (s, 3H, OCH3), 3.2 (t, 2H, CH2 (J=6.1 Hz), 3.0 (t, 2H, CH2 (J=6.0 Hz); 13C NMR (CDCl3); 24.4 (C-6), 40.8 (C-7), 198.0 (C-8), 134.6 (C-10), 128.4 (C-11,15), 129.4 (C-12,14), 133.8 (C-13), 129.7 (C-16), 129.7 (C-17,21), 114.0 (C-18,20), 166.8 (C-19), 56.1 (C-23); MS:m/z 342.08, 344.07 (M + 1), 343.08 (M + 2).


## 3.2.6. 1-(4-Methoxy-phenyl)-3-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6f)

Yield 78.00%, Yellow powder, mp (°C): 273.0; IR (Nujol, cm−1): 3076.46 (CHarom), 2744.71 (CHaliph), 1618.28 (C=O), 1556.55 (C=N), 1051.20 (C–O–C), 821.68 (CH), 590.22 (C–Cl); 1H NMR (CDCl3, 400 MHz, ppm): 8.0 (d, 2H,H-p-methoxy phenyl (J=8.9 Hz), 7.6 (m, 2H,H-o-chloro phenyl (J=8.1 Hz), 7.4 (m, 1H, H-o-chloro phenyl), 7.2 (m, 1H, H-o-chloro phenyl), 7.1 (d, 2H, H-p-methoxy phenyl (J=8.2 Hz), 3.7 (s, H, OCH3), 3.2 (t, H, CH2 (J=6.3 Hz), 3.0 (t, H, CH2 (J=6.3 Hz); 13C NMR (CDCl3); 24.2 (C-6), 40.4 (C-7), 196.9 (C-8), 137.9 (C-10), 127.4 (C-11), 134.3 (C-12), 128.9 (C-13), 130.4 (C-14), 125.1 (C-15), 128.9 (C-16), 129.5 (C-17,21), 114.0 (C-18,20), 166.9 (C-19), 56.4 (C-23); MS:m/z 342.08, 344.07 (M + 1), 343.08 (M + 2).


## 3.2.7. 1-(4-Methoxy-phenyl)-3-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6g)

Yield 79.20%, Brown crystals, mp (°C): 250–253; IR (Nujol, cm−1): 3028.24 (CHarom), 2779.42 (CHaliph), 1699.29 (C=O), 1514.12 (C=N), 1301.95 (C–O–Casymm), 1190.08 (C–O–Csymm), 908.47, 819.75, 773.46 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 7.8 (d, 2H, H-p-methoxy phenyl (J=8.4 Hz), 7.5 (d, 2H, H-p-methyl phenyl (J=8.4 Hz), 7.2 (d, 2H, H-p-methyl phenyl (J=8.3 Hz), 7.0 (d, 2H, H-p-methoxy phenyl (J=8.4 Hz), 3.7 (s, 3H, OCH3), 3.1 (t, 2H, CH2), 2.9 (t, 2H, CH2 (J=6.2 Hz), 2.3 (s, 3H, CH3 (J=6.0 Hz); 13C NMR (CDCl3); 24.9 (C-6), 41.2 (C-7), 197.4 (C-8), 133.5 (C-10), 126.6 (C-11,15), 129.3 (C-12,14), 137.7 (C-13), 129.2 (C-16), 129.4 (C-17,21), 20.9 (C-22), 114.2 (C-18,20), 166.5 (C-19), 56.0 (C-23); MS:m/z 322.13, 323.14 (M + 1), 324.11 (M + 2).


## 3.2.8. 1-(4-Methoxy-phenyl)-3-[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]propan-1-one(6h)

Yield 90.0%, yellow crystals, mp (°C): 250.00; IR (Nujol, cm−1): 3024.38, 2906 (CH), 1662.64 (C=O), 1631.78 (C=N), 1587.42 (C=C), 1517.98 (N=Oasymm), 1317.38 (N=Osymm), 1064.71 (C–O–C), 939.33, 742 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.4 (d, 2H, H-p-nitro phenyl (J=8.0 Hz), 8.2 (d, 2H, H-p-methoxy phenyl (J=7.7 Hz), 7.8 (d, 2H, H-p-nitro phenyl (J=7.8 Hz), 7.0 (d, 2H, H-p-methoxy phenyl (J=7.6 Hz), 3.7 (s, 3H, OCH3), 3.1 (t, 2H, CH2 (J=6.3 Hz), 2.9 (t, 2H, CH2 (J=6.3 Hz); 13C NMR (CDCl3); 24.4 (C-6), 40.9 (C-7), 197.6 (C-8), 142.6 (C-10), 127.9 (C-11,15), 124.1 (C-12,14), 148.4 (C-13), 129.7 (C-16), 129.6 (C-17,21), 114.0 (C-18,20), 166.4 (C-19), 56.0 (C-23); MS:m/z 353.10, 354.11 (M + 1), 355.11 (M + 2).


## 3.3. General Procedures for the Synthesis of [2-(5-Substituted-phenyl-[1,3,4]oxadiazol-2-yl)-phenyl]-phenyl-methanone(13a–h)

A mixture of12a (0.01 M), anhydrous sodium acetate (0.02 M), and glacial acetic acid was placed in round bottomed flask equipped with separating funnel for the addition of bromine. Bromine (0.8 mL in 5 mL of glacial acetic acid) was added slowly to it while stirring magnetically. After 2 hours of stirring the solution was poured on crushed ice. The resulting solid was separated, dried, and recrystallized from ethyl alcohol. Similarly compounds (13b–h) were prepared (Figure 2) [23]. The corresponding R for13a–h is given in Table 1.


### 3.3.1. {2-[5-(4-Phenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13a)

Yield 72.45%, white crystals, mp (°C): 291.00; IR (Nujol, cm−1): 3030.17 (CH), 1627.92 (C=O), 1600.92 (C=N), 1519.91 (C=C), 1219.09 (C–O–Casymm), 1043.49 (C–O–Csymm), 920.05, 779.24, 738.74 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.3 (d, 1H, H-diphenyl methanone (J=8.4 Hz), 7.9 (d, 2H, H-phenyl (J=7.7 Hz), 7.7 (m, 3H, H-diphenyl methanone (J=7.7 Hz), 7.6 (m, 1H, H-diphenyl methanone), 7.5 (m, 5H, 2H-diphenyl methanone and 3H-phenyl), 7.3 (m, 2H, diphenyl methanone); 13C NMR (CDCl3): 136.2 (C-6), 128.6 (C-7), 138.3 (C8), 130.1 (C-9), 128.7 (C-10), 130.7 (C-11), 136.5 (C-12), 127.0 (C-13,17), 129.0 (C-14,16), 128.5 (C-15), 187.0 (C-18), 137.8 (C-20), 130.1 (C-21,25), 128.2 (C-22,24), 132.2 (C-23); MS:m/z 326.14, 326.11 (M + 1), 327.11 (M + 2).


### 3.3.2. {2-[5-(4-Chlorophenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13b)

Yield 76.60%, yellow powder, mp (°C): 283–285; IR (Nujol, cm−1): 3034.03, 2918.30 (CH), 1683.86 (C=O), 1583.56 (C=N), 1521.84 (C=C), 1257.59 (C–O–Casymm), 1176.58 (CH), 1058.92 (C–O–Csymm), 925.83, 811.78, 756.10 (CH), 545.85 (C–Cl); 1H NMR (CDCl3, 400 MHz, ppm): 8.2 (d, 1H, H-diphenyl methanone) (J=7.8 Hz), 7.8 (m, 3H,H-diphenyl methanone and 2H-p-chlorophenyl), 7.6 (m, 3H,H-diphenyl methanone), 7.4 (m, 2H, diphenyl methanone (J=7.8 Hz), 7.2 (d, 4H, 2H-diphenyl methanone and 2H-p-chlorophenyl); 13C NMR (CDCl3): 136.4 (C-6), 128.5 (C-7), 138.7 (C-8), 130.5 (C-9), 128.2 (C-10), 130.9 (C-11), 134.6 (C-12), 128.4 (C-13,17), 129.4 (C-14,16), 133.8 (C-15), 187.2 (C-18), 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 360.07, 362.06 (M + 1), 363.10 (M + 2).


### 3.3.3. {2-[5-(4-Nitrophenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13c)

Yield 75.50%, brown crystals, mp (°C): 261–263; IR (Nujol, cm−1): 3115.04, 2920.23 (CH), 1651.07 (C=O), 1620.21 (C=N), 1571.99 (C=C), 1496.76 (N=Oasymm), 1365.60 (N=Osymm), 1209.37 (C–O–Casymm), 1120.64 (CH), 1047.35 (N=Osymm), 798.53 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.6 (d, 2H, H-p-nitrophenyl (J=7.7 Hz), 8.3 (m, 3H, 1H-diphenyl methanone and 2H-p-nitrophenyl), 7.9 (m, 3H, 1H-diphenyl methanone (J=8.0 Hz), 7.7 (m, 3H, 1H-diphenyl methanone (J=7.7 Hz), 7.4 (m, 2H, 1H-diphenyl methanone (J=7.9 Hz); 13C NMR (CDCl3): 136.0 (C-6), 128.2 (C-7), 138.3 (C-8), 130.9 (C-9), 128.0 (C-10), 130.4 (C-11), 142.6 (C-12), 127.9 (C-13,17), 124.1 (C-14,16), 148.4 (C-15), 186.9 (C-18), 137.9 (C-21), 128.2 (C-22,26), 127.2 (C-23,25), 129.9 (C-24); MS:m/z 371.09, 372.06 (M + 1), 373.10 (M + 2).


### 3.3.4. {2-[5-(4-Methylphenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13d)

Yield 75.50%, yellow powder, mp (°C): 257–259; IR (Nujol, cm−1): 3000 (CH), 1655.96 (C=O), 1563.337 (C=N), 1521.90 (C=C), 1236.42 (C–O–Casymm), 1111.05 (CH), 1041.61 (C–O–Csymm), 858.36, 820.75 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.5 (d, 1H, 1H-diphenyl methanone (J=7.8 Hz), 8.0 (d, 2H,p-methyl phenyl (J=8.0 Hz), 7.8 (m, 3H, diphenyl methanone (J=8.0 Hz), 7.6 (m, 3H, diphenyl methanone (J=7.9 Hz), 7.5 (m, 2H, diphenyl methanone (J=7.6 Hz), 7.1 (d, 2H,p-methyl phenyl (J=7.7 Hz), 2.4 (s, 3H, CH3); 13C NMR (CDCl3): 136.9 (C-6), 128.2 (C-7), 138.7 (C-8), 130.5 (C-9), 128.2 (C-10), 130.9 (C-11), 133.5 (C-12), 126.9 (C-13,17), 129.7 (C-14,16), 137.7 (C-15), 187.2 (C-18), 20.9 (C-20), 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 340.10, 341.12 (M + 1), 342.11 (M + 2).


### 3.3.5. {2-[5-(3-Methoxy-4-hydroxyphenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13e)

Yield 78.80%, yellow powder, mp (°C): 268–271; IR (Nujol, cm−1): 3605.11 (OH), 3073.70, 3032.23 (CH), 1662.71 (C=O), 1558.55 (C=N), 1510.33 (C=C), 1310.69 (OH), 1254.75 (C–O–C), 1117.80 (CH), 983.74, 835.21 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.4 (d, 1H, H-diphenyl methanone (J=7.9 Hz), 7.9 (m, 3H, H-diphenyl methanone (J=7.6 Hz), 7.75 (m, 3H, H-diphenyl methanone (J=7.7 Hz), 7.4 (m, 3H, 1H-p-hydroxy-3-methoxyphenyl and 2H-diphenyl methanone), 7.2 (s, 1H, 1H-p-hydroxy-3-methoxyphenyl), 6.9 (d, 1H, 1H-p-hydroxy-3-methoxypheny l (J=7.5 Hz), 5.5 (s, 1H,OH), 3.7 (s, 3H,OCH3); 13C NMR (CDCl3): 130.1 (C-6), 114.0 (C-7), 149.7 (C-8), 142.9 (C-9), 117.2 (C-10), 120.7 (C-11), 136.8 (C-12), 127.9 (C-13), 138.0 (C-14), 129.4 (C-15), 128.4 (C-16), 130.1 (C-17), 56.3 (C-18), 188.1 (C-20), 137.8 (C-21), 129.9 (C-23,27), 128.5 (C-24,26), 131.9 (C-25); MS:m/z 372.11, 373.13 (M + 1), 374.12 (M + 2).


### 3.3.6. {2-[5-(4-Hydroxyphenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13f)

Yield 80.0%, light yellow powder, mp (°C): 294-295; IR (Nujol, cm−1): 3624.25 (OH), 3024.38 (CH), 1667.14 (C=O), 1589.34 (C=N), 1554.63 (C=C), 1402.25 (OH), 1247.94 (C–O–C), 1126.43 (CH), 933.70, 862.18, 769.60 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.3 (d, 1H, H-diphenyl methanone (J=8.1 Hz), 7.9 (m, 5H, 2H-4-hydroxy phenyl, 3H-diphenyl methanone), 7.6 (m, 3H, H-diphenyl methanone (J=7.8 Hz), 7.39 (m, 2H, H-diphenyl methanone (J=7.8 Hz), 7.3 (m, 2H, H-diphenyl methanone (J=8.1 Hz), 6.9 (d, 2H,H-p-hydroxy phenyl (J=7.8 Hz), 5.09 (s, 1H,OH); 13C NMR (CDCl3): 136.9 (C-6), 128.2 (C-7), 138.7 (C-8), 130.5 (C-9), 128.2 (C-10), 130.9 (C-11), 129.1 (C-12), 128.4 (C-13,17), 116.2 (C-14,16), 157.3 (C-15), 187.2 (C-18), 20.9 (C-20) 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 342.10, 343.18 (M + 1), 344.11 (M + 2).


### 3.3.7. {2-[5-(2-Nitrophenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13g)

Yield 75.85%, yellow crystals, mp (°C): 237–239; IR (Nujol, cm−1): 2920.35 (CH), 1668.50 (C=O), 1522.87 (C=N), 1518.04 (C=C), 1511.29 (N=Oasymm), 1371.45 (N=Osymm), 1265.36 (C–O–C), 1160.23, 1108.15, 1098.51 (CH), 758.06 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.3 (d, 1H, H-diphenyl methanone (J=8.2 Hz), 8.0 (m, 2H,o-nitrophenyl (J=7.7 Hz), 7.7 (m, 4H, 1H-o-nitrophenyl and 3H-diphenyl methanone), 7.5 (m, 2H, 1H-o-nitrophenyl and 1H-diphenyl methanone), 7.4 (m, 4H, H-diphenyl methanone (J=7.8 Hz); 13C NMR (CDCl3): 131.6 (C-6), 146.9 (C-7), 124.1 (C-8), 129.4 (C-9), 135.1 (C-10), 127.9 (C-11), 135.9 (C-12), 127.9 (C-13), 138.0 (C-14), 129.4 (C-15), 128.4 (C-16), 130.1 (C-17), 187.0 (C-19), 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 371.10, 372.09 (M + 1), 373.10 (M + 2).


### 3.3.8. {2-[5-(2-Hydroxyphenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13h)

Yield 78.0%, yellow crystals, mp (°C): 254-255; IR (Nujol, cm−1): 3381.21 (OH), 2987.74 (CH), 1602.85 (C=O), 1591.27 (C=N), 1352.10 (OH), 1070.49 (C–O–C), 742.59 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.5 (s, 1H, OH), 8.39 (d, 1H, H-diphenyl methanone (J=8.5 Hz), 7.81 (m, 3H, H-diphenyl methanone (J=7.5 Hz), 7.61 (m, 5H, H-diphenyl methanone ando-hydroxy phenyl), 7.3 (m, 1H, H-diphenyl methanone (J=8.2 Hz), 6.8 (m, 1H,o-hydroxy phenyl (J=7.7 Hz), 6.7 (m, 1H,o-hydroxy phenyl (J=7.6 Hz), 6.5 (m, 1H,o-hydroxy phenyl (J=7.7 Hz); 13C NMR (CDCl3): 123.7 (C-6), 155.8 (C-7), 116.2 (C-8), 129.9 (C-9), 121.6 (C-10), 128.4 (C-11), 135.9 (C-12), 127.9 (C-13), 138.0 (C-14), 129.4 (C-15), 128.4 (C-16), 130.1 (C-17), 187.0 (C-19), 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 342.10, 343.12 (M + 1), 344.11 (M + 2).


## 3.3.1. {2-[5-(4-Phenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13a)

Yield 72.45%, white crystals, mp (°C): 291.00; IR (Nujol, cm−1): 3030.17 (CH), 1627.92 (C=O), 1600.92 (C=N), 1519.91 (C=C), 1219.09 (C–O–Casymm), 1043.49 (C–O–Csymm), 920.05, 779.24, 738.74 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.3 (d, 1H, H-diphenyl methanone (J=8.4 Hz), 7.9 (d, 2H, H-phenyl (J=7.7 Hz), 7.7 (m, 3H, H-diphenyl methanone (J=7.7 Hz), 7.6 (m, 1H, H-diphenyl methanone), 7.5 (m, 5H, 2H-diphenyl methanone and 3H-phenyl), 7.3 (m, 2H, diphenyl methanone); 13C NMR (CDCl3): 136.2 (C-6), 128.6 (C-7), 138.3 (C8), 130.1 (C-9), 128.7 (C-10), 130.7 (C-11), 136.5 (C-12), 127.0 (C-13,17), 129.0 (C-14,16), 128.5 (C-15), 187.0 (C-18), 137.8 (C-20), 130.1 (C-21,25), 128.2 (C-22,24), 132.2 (C-23); MS:m/z 326.14, 326.11 (M + 1), 327.11 (M + 2).


## 3.3.2. {2-[5-(4-Chlorophenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13b)

Yield 76.60%, yellow powder, mp (°C): 283–285; IR (Nujol, cm−1): 3034.03, 2918.30 (CH), 1683.86 (C=O), 1583.56 (C=N), 1521.84 (C=C), 1257.59 (C–O–Casymm), 1176.58 (CH), 1058.92 (C–O–Csymm), 925.83, 811.78, 756.10 (CH), 545.85 (C–Cl); 1H NMR (CDCl3, 400 MHz, ppm): 8.2 (d, 1H, H-diphenyl methanone) (J=7.8 Hz), 7.8 (m, 3H,H-diphenyl methanone and 2H-p-chlorophenyl), 7.6 (m, 3H,H-diphenyl methanone), 7.4 (m, 2H, diphenyl methanone (J=7.8 Hz), 7.2 (d, 4H, 2H-diphenyl methanone and 2H-p-chlorophenyl); 13C NMR (CDCl3): 136.4 (C-6), 128.5 (C-7), 138.7 (C-8), 130.5 (C-9), 128.2 (C-10), 130.9 (C-11), 134.6 (C-12), 128.4 (C-13,17), 129.4 (C-14,16), 133.8 (C-15), 187.2 (C-18), 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 360.07, 362.06 (M + 1), 363.10 (M + 2).


## 3.3.3. {2-[5-(4-Nitrophenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13c)

Yield 75.50%, brown crystals, mp (°C): 261–263; IR (Nujol, cm−1): 3115.04, 2920.23 (CH), 1651.07 (C=O), 1620.21 (C=N), 1571.99 (C=C), 1496.76 (N=Oasymm), 1365.60 (N=Osymm), 1209.37 (C–O–Casymm), 1120.64 (CH), 1047.35 (N=Osymm), 798.53 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.6 (d, 2H, H-p-nitrophenyl (J=7.7 Hz), 8.3 (m, 3H, 1H-diphenyl methanone and 2H-p-nitrophenyl), 7.9 (m, 3H, 1H-diphenyl methanone (J=8.0 Hz), 7.7 (m, 3H, 1H-diphenyl methanone (J=7.7 Hz), 7.4 (m, 2H, 1H-diphenyl methanone (J=7.9 Hz); 13C NMR (CDCl3): 136.0 (C-6), 128.2 (C-7), 138.3 (C-8), 130.9 (C-9), 128.0 (C-10), 130.4 (C-11), 142.6 (C-12), 127.9 (C-13,17), 124.1 (C-14,16), 148.4 (C-15), 186.9 (C-18), 137.9 (C-21), 128.2 (C-22,26), 127.2 (C-23,25), 129.9 (C-24); MS:m/z 371.09, 372.06 (M + 1), 373.10 (M + 2).


## 3.3.4. {2-[5-(4-Methylphenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13d)

Yield 75.50%, yellow powder, mp (°C): 257–259; IR (Nujol, cm−1): 3000 (CH), 1655.96 (C=O), 1563.337 (C=N), 1521.90 (C=C), 1236.42 (C–O–Casymm), 1111.05 (CH), 1041.61 (C–O–Csymm), 858.36, 820.75 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.5 (d, 1H, 1H-diphenyl methanone (J=7.8 Hz), 8.0 (d, 2H,p-methyl phenyl (J=8.0 Hz), 7.8 (m, 3H, diphenyl methanone (J=8.0 Hz), 7.6 (m, 3H, diphenyl methanone (J=7.9 Hz), 7.5 (m, 2H, diphenyl methanone (J=7.6 Hz), 7.1 (d, 2H,p-methyl phenyl (J=7.7 Hz), 2.4 (s, 3H, CH3); 13C NMR (CDCl3): 136.9 (C-6), 128.2 (C-7), 138.7 (C-8), 130.5 (C-9), 128.2 (C-10), 130.9 (C-11), 133.5 (C-12), 126.9 (C-13,17), 129.7 (C-14,16), 137.7 (C-15), 187.2 (C-18), 20.9 (C-20), 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 340.10, 341.12 (M + 1), 342.11 (M + 2).


## 3.3.5. {2-[5-(3-Methoxy-4-hydroxyphenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13e)

Yield 78.80%, yellow powder, mp (°C): 268–271; IR (Nujol, cm−1): 3605.11 (OH), 3073.70, 3032.23 (CH), 1662.71 (C=O), 1558.55 (C=N), 1510.33 (C=C), 1310.69 (OH), 1254.75 (C–O–C), 1117.80 (CH), 983.74, 835.21 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.4 (d, 1H, H-diphenyl methanone (J=7.9 Hz), 7.9 (m, 3H, H-diphenyl methanone (J=7.6 Hz), 7.75 (m, 3H, H-diphenyl methanone (J=7.7 Hz), 7.4 (m, 3H, 1H-p-hydroxy-3-methoxyphenyl and 2H-diphenyl methanone), 7.2 (s, 1H, 1H-p-hydroxy-3-methoxyphenyl), 6.9 (d, 1H, 1H-p-hydroxy-3-methoxypheny l (J=7.5 Hz), 5.5 (s, 1H,OH), 3.7 (s, 3H,OCH3); 13C NMR (CDCl3): 130.1 (C-6), 114.0 (C-7), 149.7 (C-8), 142.9 (C-9), 117.2 (C-10), 120.7 (C-11), 136.8 (C-12), 127.9 (C-13), 138.0 (C-14), 129.4 (C-15), 128.4 (C-16), 130.1 (C-17), 56.3 (C-18), 188.1 (C-20), 137.8 (C-21), 129.9 (C-23,27), 128.5 (C-24,26), 131.9 (C-25); MS:m/z 372.11, 373.13 (M + 1), 374.12 (M + 2).


## 3.3.6. {2-[5-(4-Hydroxyphenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13f)

Yield 80.0%, light yellow powder, mp (°C): 294-295; IR (Nujol, cm−1): 3624.25 (OH), 3024.38 (CH), 1667.14 (C=O), 1589.34 (C=N), 1554.63 (C=C), 1402.25 (OH), 1247.94 (C–O–C), 1126.43 (CH), 933.70, 862.18, 769.60 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.3 (d, 1H, H-diphenyl methanone (J=8.1 Hz), 7.9 (m, 5H, 2H-4-hydroxy phenyl, 3H-diphenyl methanone), 7.6 (m, 3H, H-diphenyl methanone (J=7.8 Hz), 7.39 (m, 2H, H-diphenyl methanone (J=7.8 Hz), 7.3 (m, 2H, H-diphenyl methanone (J=8.1 Hz), 6.9 (d, 2H,H-p-hydroxy phenyl (J=7.8 Hz), 5.09 (s, 1H,OH); 13C NMR (CDCl3): 136.9 (C-6), 128.2 (C-7), 138.7 (C-8), 130.5 (C-9), 128.2 (C-10), 130.9 (C-11), 129.1 (C-12), 128.4 (C-13,17), 116.2 (C-14,16), 157.3 (C-15), 187.2 (C-18), 20.9 (C-20) 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 342.10, 343.18 (M + 1), 344.11 (M + 2).


## 3.3.7. {2-[5-(2-Nitrophenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13g)

Yield 75.85%, yellow crystals, mp (°C): 237–239; IR (Nujol, cm−1): 2920.35 (CH), 1668.50 (C=O), 1522.87 (C=N), 1518.04 (C=C), 1511.29 (N=Oasymm), 1371.45 (N=Osymm), 1265.36 (C–O–C), 1160.23, 1108.15, 1098.51 (CH), 758.06 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.3 (d, 1H, H-diphenyl methanone (J=8.2 Hz), 8.0 (m, 2H,o-nitrophenyl (J=7.7 Hz), 7.7 (m, 4H, 1H-o-nitrophenyl and 3H-diphenyl methanone), 7.5 (m, 2H, 1H-o-nitrophenyl and 1H-diphenyl methanone), 7.4 (m, 4H, H-diphenyl methanone (J=7.8 Hz); 13C NMR (CDCl3): 131.6 (C-6), 146.9 (C-7), 124.1 (C-8), 129.4 (C-9), 135.1 (C-10), 127.9 (C-11), 135.9 (C-12), 127.9 (C-13), 138.0 (C-14), 129.4 (C-15), 128.4 (C-16), 130.1 (C-17), 187.0 (C-19), 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 371.10, 372.09 (M + 1), 373.10 (M + 2).


## 3.3.8. {2-[5-(2-Hydroxyphenyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-phenyl-methanone(13h)

Yield 78.0%, yellow crystals, mp (°C): 254-255; IR (Nujol, cm−1): 3381.21 (OH), 2987.74 (CH), 1602.85 (C=O), 1591.27 (C=N), 1352.10 (OH), 1070.49 (C–O–C), 742.59 (CH); 1H NMR (CDCl3, 400 MHz, ppm): 8.5 (s, 1H, OH), 8.39 (d, 1H, H-diphenyl methanone (J=8.5 Hz), 7.81 (m, 3H, H-diphenyl methanone (J=7.5 Hz), 7.61 (m, 5H, H-diphenyl methanone ando-hydroxy phenyl), 7.3 (m, 1H, H-diphenyl methanone (J=8.2 Hz), 6.8 (m, 1H,o-hydroxy phenyl (J=7.7 Hz), 6.7 (m, 1H,o-hydroxy phenyl (J=7.6 Hz), 6.5 (m, 1H,o-hydroxy phenyl (J=7.7 Hz); 13C NMR (CDCl3): 123.7 (C-6), 155.8 (C-7), 116.2 (C-8), 129.9 (C-9), 121.6 (C-10), 128.4 (C-11), 135.9 (C-12), 127.9 (C-13), 138.0 (C-14), 129.4 (C-15), 128.4 (C-16), 130.1 (C-17), 187.0 (C-19), 137.4 (C-21), 130.6 (C-22,26), 128.8 (C-23,25), 131.9 (C-24); MS:m/z 342.10, 343.12 (M + 1), 344.11 (M + 2).


## 4. Antibacterial Evaluation

### 4.1. Antibacterial Activity

The antibacterial evaluation was carried out by using agar cup-plate method. The microorganismsEscherichia coli,Pseudomonas aeruginosa,Staphylococcus epidermidis, andStaphylococcus aureus were used for the antibacterial evaluation. Nutrient agar media were prepared and then inoculated with fresh prepared culture media. The inoculated media were poured into Petri dish and allowed to set. Cups were made by punching the agar surface with a sterile cork bore (8 mm). Solutions containing 10, 12.5, 25, 50, 100, 200, 400, 800, and 1600 μg/mL of the test derivatives in dimethyl formamide (DMF) were added to each cup. Amoxicillin and cefixime were taken as positive control and DMF was taken as blank. The plates were incubated at 37°C for 24 hours and the results were recorded. The zones of inhibition of the microbial growth produced by different concentration of test compounds were measured in millimeters [24, 25]. The zone of inhibition data for antibacterial compounds is summarized in Table 3.Table 3
Zone of inhibition of synthesized 1,3,4-oxadiazole derivatives against selected microbial strains.
Compound
Concentration  (µg/mL)
Zone of inhibition (mm)
E. coli
P. aeruginosa
S.  aureus
S. epidermidis
6a
100
16.00
±
0.20
—
10.81
±
0.50
12.17
±
0.16
200
21.80
±
0.15
—
11.80
±
0.40
14.98
±
0.22
400
21.93
±
0.20
—
11.00
±
0.08
15.98
±
0.23
6b
100
15.90
±
0.90
—
15.03
±
0.10
14.01
±
0.34
200
18.99
±
0.10
12.02
±
0.18
16.01
±
0.21
13.17
±
0.17
400
21.96
±
0.17
12.12
±
0.14
16.06
±
0.21
18.00
±
0.31
6c
100
13.11
±
0.20
—
14.11
±
0.11
—
200
14.01
±
0.02
—
17.03
±
0.25
11.01
±
0.13
400
15.97
±
0.27
—
17.06
±
0.18
12.15
±
0.15
6d
100
14.03
±
0.19
12.03
±
0.23
15.11
±
0.12
—
200
15.00
±
0.11
14.11
±
0.11
16.17
±
0.17
14.07
±
0.24
400
16.03
±
0.18
14.06
±
0.25
16.71
±
0.10
15.10
±
0.11
6e
100
20.02
±
0.09
14.12
±
0.12
15.00
±
0.10
16.98
±
0.23
200
27.04
±
0.27
20.04
±
0.12
23.47
±
0.45
25.18
±
0.23
400
27.82
±
0.16
20.63
±
0.16
24.60
±
0.11
25.86
±
0.17
6f
100
15.93
±
0.40
14.13
±
0.11
12.05
±
0.23
20.13
±
0.11
200
24.85
±
0.14
19.91
±
0.13
15.90
±
0.18
24.17
±
0.20
400
25.94
±
0.15
20.00
±
0.35
16.06
±
0.25
24.88
±
0.13
6g
100
16.11
±
0.11
—
14.12
±
0.13
12.20
±
0.20
200
20.01
±
0.19
—
18.16
±
0.50
15.10
±
0.13
400
20.09
±
0.18
—
20.21
±
0.25
16.00
±
0.33
6h
100
15.93
±
0.06
—
15.91
±
.
090
14.06
±
0.29
200
20.18
±
0.50
12.05
±
0.26
19.12
±
0.11
13.09
±
0.13
400
20.80
±
0.12
12.45
±
0.18
22.01
±
0.10
17.90
±
0.24
13a
50
20.97
±
0.17
18.40
±
0.16
15.99
±
0.14
12.91
±
0.06
100
21.06
±
0.24
19.16
±
0.50
19.96
±
0.22
18.16
±
0.50
200
21.95
±
0.24
22.20
±
0.19
22.18
±
0.22
19.80
±
0.19
13b
50
19.89
±
0.11
13.10
±
0.15
22.07
±
0.21
16.05
±
0.31
100
27.85
±
0.16
17.99
±
0.01
25.04
±
0.27
25.03
±
0.26
200
28.95
±
0.18
18.11
±
0.11
26.16
±
0.18
26.90
±
0.14
13c
50
22.10
±
0.09
15.91
±
0.50
24.04
±
0.07
20.10
±
0.11
100
27.05
±
0.12
20.89
±
0.11
26.95
±
0.23
27.00
±
0.17
200
28.15
±
0.18
22.13
±
0.15
27.08
±
0.24
28.00
±
0.08
13d
50
14.06
±
0.11
20.02
±
0.18
16.01
±
0.21
20.00
±
0.07
100
18.11
±
0.10
22.80
±
0.19
19.07
±
0.06
26.13
±
0.11
200
18.09
±
0.12
22.84
±
0.15
19.86
±
0.50
28.03
±
0.14
13e
50
24.02
±
0.12
16.00
±
0.02
24.01
±
0.28
24.00
±
0.20
100
27.15
±
0.18
21.00
±
0.18
27.05
±
0.33
26.00
±
0.17
200
28.01
±
0.18
22.17
±
0.20
28.34
±
0.24
28.08
±
0.07
13f
50
18.13
±
0.33
16.11
±
0.11
14.84
±
0.19
11.81
±
0.15
100
20.10
±
0.10
21.97
±
0.18
14.84
±
0.19
18.03
±
0.12
200
20.13
±
0.15
21.90
±
0.20
15.98
±
0.27
18.16
±
0.19
13g
50
14.12
±
0.13
11.91
±
0.90
16.05
±
0.26
16.00
±
0.22
100
24.02
±
0.14
15.21
±
0.25
19.90
±
0.06
26.14
±
0.15
200
25.86
±
0.15
15.95
±
0.06
19.98
±
0.13
27.91
±
0.08
13h
50
20.03
±
0.15
11.10
±
0.09
14.01
±
0.32
19.80
±
0.19
100
21.14
±
0.15
12.90
±
0.15
16.34
±
0.24
22.03
±
0.34
200
21.05
±
0.24
13.00
±
0.17
16.98
±
0.17
23.09
±
0.09
Amoxicillin
200
22.00
±
0.67
—
10.98
±
0.10
24.09
±
0.10
400
26.20
±
0.44
12.11
±
0.11
14.19
±
0.18
27.99
±
0.10
800
30.00
±
0.10
13.99
±
0.23
18.12
±
0.12
32.06
±
0.22
Cefixime
200
16.00
±
0.28
—
—
14.88
±
0.12
400
18.15
±
0.17
—
—
15.99
±
0.30
800
22.18
±
0.22
12.00
±
0.38
12.03
±
0.19
20.03
±
0.15
Values are expressed as mean ± standard deviation of the three replicates.
Diameter of the well is not included in zone of inhibition.


### 4.2. Minimum Inhibitory Concentration (MIC)

Nutrient agar was prepared, sterilized, and cooled to 45°C with gentle shaking to bring about uniform cooling. It was inoculated with 0.5-0.6 mL of culture and mixed well by gentle shaking before pouring into the sterilized petri dishes. The poured materials were allowed to set and thereafter the cups were made by punching into the agar surface with sterile cork borer and scooping out the punched part of the agar. 0.1 mL of each test compounds was added into the cups with the help of sterile syringe. Twofold diluted solutions of the compounds and reference drugs were used (6.5, 12.5, 25, 50, 100, 200, 400, 800, and 1600μg/mL). The drug solutions were allowed to diffuse for some time into the medium. The plates were incubated at 30–35°C for 24–48 hours. The incubation chamber was kept sufficiently humid. MIC values were determined at the end of the incubation period. The MIC values for synthesized compounds are summarized in Table 4 and graphical representation of MIC of synthesized 1,3,4-oxadiazole derivatives and standard drugs against gram negative and gram positive bacterial strains are given in Figures 3 and 4 (Table 4), respectively [24, 25].Table 4
Minimum inhibitory concentrations (MIC) of synthesized 1,3,4-oxadiazole derivatives.
Compound
MIC (µg/mL)
E.  coli
P. aeruginosa
S.  aureus
S.  epidermidis
C.  albicans
A.  niger
6a
50
100
50
200
50
100
6b
50
200
50
100
25
200
6c
25
200
100
100
200
50
6d
200
200
100
200
200
100
6e
25
100
25
100
200
50
6f
12.5
100
100
12.5
12.5
25
6g
50
100
100
50
25
25
6h
25
100
50
25
50
200
13a
25
200
25
50
50
50
13b
12.5
12.5
100
12.5
12.5
10
13c
25
25
100
25
25
10
13d
25
25
50
50
50
50
13e
12.5
25
25
25
100
10
13f
50
50
100
25
25
25
13g
50
25
50
50
50
100
13h
50
100
200
25
100
200
Control
—
—
—
—
—
—
Amoxicillin
12.5
200
100
12.5
—
—
Cefixime
50
400
400
50
—
—
Fluconazole
—
—
—
—
12.5
400Figure 3
Minimum inhibitory concentrations (MIC) of synthesized 1,3,4-oxadiazole derivatives and standard drugs against gram negative bacterial strains.Figure 4
Minimum inhibitory concentrations (MIC) of synthesized 1,3,4-oxadiazole derivatives and standard drugs against gram positive bacterial strains.


### 4.3. QSAR Analysis

The compounds were analyzed by multiple regression analysis, a QSAR approach using different physicochemical parameters as independent and biological activity as dependent variables [26]. Multiple linear regression efforts to maximize the fit of the data to a QSAR model for the biological activity by correcting each of the existing parameters. Successive regression models will be generated in which parameters will be either added or removed until the maximum r2 and minimum S are obtained. The extent of coefficients obtained in this routine specifies the virtual contribution of the associated parameters to biological activity.Biological activity data was converted to the logarithmic value. The biological activities used in the present studies were expressed as pMIC50; logarithm of a reciprocal concentration for 50% inhibition where MIC50 is the minimum inhibitory concentration of the compounds producing 50% reduction in the effect caused by bacteria (Escherichia coli, Pseudomonas aeruginosa, Staphylococcus epidermidis, andStaphylococcus aureus) is stated as a mean of at least three experiments for 24 compounds [26, 27].The physicochemical parameters were computed (Table5) using Chem 3D Ultra 10 after energy minimization to minimum root mean square (RMS) gradient of 0.100 kcal/mole Å by MOPAC software package. The parameters LogP, SAS, MR, ovality, MSA, and MW were selected in QSAR studies which are having significant effect on biological activity.Table 5
Observed and predicted antibacterial activity of synthesized 1,3,4-oxadiazole derivatives  againstEscherichia coli and Pseudomonas aeruginosa.
Compounds
Observed  activity
Calculated  activity
Residuals
Observed  activity
Calculated  activity
Residuals
6a
1.39794
1.42696
−0.02902
1.39794
1.380355
0.017585
6b
1.39794
1.49081
−0.09287
—
—
—
6c
—
—
1.69897
1.693166
0.005804
6d
—
—
—
1.69897
1.749717
−0.05075
6e
1.09691
1.17324
−0.07633
—
—
—
6f
—
—
—
1.69897
1.739458
−0.04049
6g
1.39794
1.28492
0.113024
1.69897
1.565732
0.133238
8a
1.09691
1.10285
−0.00594
—
—
—
8b
1.09691
1.22329
−0.12638
—
—
—
8c
1.09691
1.01685
0.080062
—
—
—
8d
2
1.95106
0.048936
2
2.143298
−0.1433
8e
—
—
—
—
—
—
8f
1.69897
1.66784
0.031132
—
—
—
8g
1.09691
1.0879
0.009007
1.39794
1.417768
−0.01983
13a
1.09691
1.2223
−0.12539
1.09691
1.241458
−0.14455
13b
0.79588
0.9957
−0.19982
1.69897
1.59415
0.10482
13d
1.09691
1.13534
−0.03843
1.39794
1.422187
−0.02425
13e
0.79588
0.80956
−0.01368
—
—
—
13f
1.39794
1.03279
0.365149
1.69897
1.642724
0.056246
13h
1.09691
1.11426
−0.01735
2
1.769982
0.230018
(—) Compounds are not included in QSAR model development.


### 4.4. Molecular Docking Studies

Docking studies reported here IN were performed using software Molegro Virtual Docker 5.0.0.The newly synthesized 1,3,4-oxadiazoles derivatives were computationally designed and optimized to investigate the interactions between the target compounds and the amino acid residues of theE. coli PDF.Ni enzyme by molecular docking [15]. Target compounds were docked into active site of PDF (PDB code 1G2A) using MVD (version 5.0.0.) software to observe the affinity for the enzyme and also compared their binding energies with standard drugs such as amoxicillin and cefixime.


## 4.1. Antibacterial Activity

The antibacterial evaluation was carried out by using agar cup-plate method. The microorganismsEscherichia coli,Pseudomonas aeruginosa,Staphylococcus epidermidis, andStaphylococcus aureus were used for the antibacterial evaluation. Nutrient agar media were prepared and then inoculated with fresh prepared culture media. The inoculated media were poured into Petri dish and allowed to set. Cups were made by punching the agar surface with a sterile cork bore (8 mm). Solutions containing 10, 12.5, 25, 50, 100, 200, 400, 800, and 1600 μg/mL of the test derivatives in dimethyl formamide (DMF) were added to each cup. Amoxicillin and cefixime were taken as positive control and DMF was taken as blank. The plates were incubated at 37°C for 24 hours and the results were recorded. The zones of inhibition of the microbial growth produced by different concentration of test compounds were measured in millimeters [24, 25]. The zone of inhibition data for antibacterial compounds is summarized in Table 3.Table 3
Zone of inhibition of synthesized 1,3,4-oxadiazole derivatives against selected microbial strains.
Compound
Concentration  (µg/mL)
Zone of inhibition (mm)
E. coli
P. aeruginosa
S.  aureus
S. epidermidis
6a
100
16.00
±
0.20
—
10.81
±
0.50
12.17
±
0.16
200
21.80
±
0.15
—
11.80
±
0.40
14.98
±
0.22
400
21.93
±
0.20
—
11.00
±
0.08
15.98
±
0.23
6b
100
15.90
±
0.90
—
15.03
±
0.10
14.01
±
0.34
200
18.99
±
0.10
12.02
±
0.18
16.01
±
0.21
13.17
±
0.17
400
21.96
±
0.17
12.12
±
0.14
16.06
±
0.21
18.00
±
0.31
6c
100
13.11
±
0.20
—
14.11
±
0.11
—
200
14.01
±
0.02
—
17.03
±
0.25
11.01
±
0.13
400
15.97
±
0.27
—
17.06
±
0.18
12.15
±
0.15
6d
100
14.03
±
0.19
12.03
±
0.23
15.11
±
0.12
—
200
15.00
±
0.11
14.11
±
0.11
16.17
±
0.17
14.07
±
0.24
400
16.03
±
0.18
14.06
±
0.25
16.71
±
0.10
15.10
±
0.11
6e
100
20.02
±
0.09
14.12
±
0.12
15.00
±
0.10
16.98
±
0.23
200
27.04
±
0.27
20.04
±
0.12
23.47
±
0.45
25.18
±
0.23
400
27.82
±
0.16
20.63
±
0.16
24.60
±
0.11
25.86
±
0.17
6f
100
15.93
±
0.40
14.13
±
0.11
12.05
±
0.23
20.13
±
0.11
200
24.85
±
0.14
19.91
±
0.13
15.90
±
0.18
24.17
±
0.20
400
25.94
±
0.15
20.00
±
0.35
16.06
±
0.25
24.88
±
0.13
6g
100
16.11
±
0.11
—
14.12
±
0.13
12.20
±
0.20
200
20.01
±
0.19
—
18.16
±
0.50
15.10
±
0.13
400
20.09
±
0.18
—
20.21
±
0.25
16.00
±
0.33
6h
100
15.93
±
0.06
—
15.91
±
.
090
14.06
±
0.29
200
20.18
±
0.50
12.05
±
0.26
19.12
±
0.11
13.09
±
0.13
400
20.80
±
0.12
12.45
±
0.18
22.01
±
0.10
17.90
±
0.24
13a
50
20.97
±
0.17
18.40
±
0.16
15.99
±
0.14
12.91
±
0.06
100
21.06
±
0.24
19.16
±
0.50
19.96
±
0.22
18.16
±
0.50
200
21.95
±
0.24
22.20
±
0.19
22.18
±
0.22
19.80
±
0.19
13b
50
19.89
±
0.11
13.10
±
0.15
22.07
±
0.21
16.05
±
0.31
100
27.85
±
0.16
17.99
±
0.01
25.04
±
0.27
25.03
±
0.26
200
28.95
±
0.18
18.11
±
0.11
26.16
±
0.18
26.90
±
0.14
13c
50
22.10
±
0.09
15.91
±
0.50
24.04
±
0.07
20.10
±
0.11
100
27.05
±
0.12
20.89
±
0.11
26.95
±
0.23
27.00
±
0.17
200
28.15
±
0.18
22.13
±
0.15
27.08
±
0.24
28.00
±
0.08
13d
50
14.06
±
0.11
20.02
±
0.18
16.01
±
0.21
20.00
±
0.07
100
18.11
±
0.10
22.80
±
0.19
19.07
±
0.06
26.13
±
0.11
200
18.09
±
0.12
22.84
±
0.15
19.86
±
0.50
28.03
±
0.14
13e
50
24.02
±
0.12
16.00
±
0.02
24.01
±
0.28
24.00
±
0.20
100
27.15
±
0.18
21.00
±
0.18
27.05
±
0.33
26.00
±
0.17
200
28.01
±
0.18
22.17
±
0.20
28.34
±
0.24
28.08
±
0.07
13f
50
18.13
±
0.33
16.11
±
0.11
14.84
±
0.19
11.81
±
0.15
100
20.10
±
0.10
21.97
±
0.18
14.84
±
0.19
18.03
±
0.12
200
20.13
±
0.15
21.90
±
0.20
15.98
±
0.27
18.16
±
0.19
13g
50
14.12
±
0.13
11.91
±
0.90
16.05
±
0.26
16.00
±
0.22
100
24.02
±
0.14
15.21
±
0.25
19.90
±
0.06
26.14
±
0.15
200
25.86
±
0.15
15.95
±
0.06
19.98
±
0.13
27.91
±
0.08
13h
50
20.03
±
0.15
11.10
±
0.09
14.01
±
0.32
19.80
±
0.19
100
21.14
±
0.15
12.90
±
0.15
16.34
±
0.24
22.03
±
0.34
200
21.05
±
0.24
13.00
±
0.17
16.98
±
0.17
23.09
±
0.09
Amoxicillin
200
22.00
±
0.67
—
10.98
±
0.10
24.09
±
0.10
400
26.20
±
0.44
12.11
±
0.11
14.19
±
0.18
27.99
±
0.10
800
30.00
±
0.10
13.99
±
0.23
18.12
±
0.12
32.06
±
0.22
Cefixime
200
16.00
±
0.28
—
—
14.88
±
0.12
400
18.15
±
0.17
—
—
15.99
±
0.30
800
22.18
±
0.22
12.00
±
0.38
12.03
±
0.19
20.03
±
0.15
Values are expressed as mean ± standard deviation of the three replicates.
Diameter of the well is not included in zone of inhibition.


## 4.2. Minimum Inhibitory Concentration (MIC)

Nutrient agar was prepared, sterilized, and cooled to 45°C with gentle shaking to bring about uniform cooling. It was inoculated with 0.5-0.6 mL of culture and mixed well by gentle shaking before pouring into the sterilized petri dishes. The poured materials were allowed to set and thereafter the cups were made by punching into the agar surface with sterile cork borer and scooping out the punched part of the agar. 0.1 mL of each test compounds was added into the cups with the help of sterile syringe. Twofold diluted solutions of the compounds and reference drugs were used (6.5, 12.5, 25, 50, 100, 200, 400, 800, and 1600μg/mL). The drug solutions were allowed to diffuse for some time into the medium. The plates were incubated at 30–35°C for 24–48 hours. The incubation chamber was kept sufficiently humid. MIC values were determined at the end of the incubation period. The MIC values for synthesized compounds are summarized in Table 4 and graphical representation of MIC of synthesized 1,3,4-oxadiazole derivatives and standard drugs against gram negative and gram positive bacterial strains are given in Figures 3 and 4 (Table 4), respectively [24, 25].Table 4
Minimum inhibitory concentrations (MIC) of synthesized 1,3,4-oxadiazole derivatives.
Compound
MIC (µg/mL)
E.  coli
P. aeruginosa
S.  aureus
S.  epidermidis
C.  albicans
A.  niger
6a
50
100
50
200
50
100
6b
50
200
50
100
25
200
6c
25
200
100
100
200
50
6d
200
200
100
200
200
100
6e
25
100
25
100
200
50
6f
12.5
100
100
12.5
12.5
25
6g
50
100
100
50
25
25
6h
25
100
50
25
50
200
13a
25
200
25
50
50
50
13b
12.5
12.5
100
12.5
12.5
10
13c
25
25
100
25
25
10
13d
25
25
50
50
50
50
13e
12.5
25
25
25
100
10
13f
50
50
100
25
25
25
13g
50
25
50
50
50
100
13h
50
100
200
25
100
200
Control
—
—
—
—
—
—
Amoxicillin
12.5
200
100
12.5
—
—
Cefixime
50
400
400
50
—
—
Fluconazole
—
—
—
—
12.5
400Figure 3
Minimum inhibitory concentrations (MIC) of synthesized 1,3,4-oxadiazole derivatives and standard drugs against gram negative bacterial strains.Figure 4
Minimum inhibitory concentrations (MIC) of synthesized 1,3,4-oxadiazole derivatives and standard drugs against gram positive bacterial strains.


## 4.3. QSAR Analysis

The compounds were analyzed by multiple regression analysis, a QSAR approach using different physicochemical parameters as independent and biological activity as dependent variables [26]. Multiple linear regression efforts to maximize the fit of the data to a QSAR model for the biological activity by correcting each of the existing parameters. Successive regression models will be generated in which parameters will be either added or removed until the maximum r2 and minimum S are obtained. The extent of coefficients obtained in this routine specifies the virtual contribution of the associated parameters to biological activity.Biological activity data was converted to the logarithmic value. The biological activities used in the present studies were expressed as pMIC50; logarithm of a reciprocal concentration for 50% inhibition where MIC50 is the minimum inhibitory concentration of the compounds producing 50% reduction in the effect caused by bacteria (Escherichia coli, Pseudomonas aeruginosa, Staphylococcus epidermidis, andStaphylococcus aureus) is stated as a mean of at least three experiments for 24 compounds [26, 27].The physicochemical parameters were computed (Table5) using Chem 3D Ultra 10 after energy minimization to minimum root mean square (RMS) gradient of 0.100 kcal/mole Å by MOPAC software package. The parameters LogP, SAS, MR, ovality, MSA, and MW were selected in QSAR studies which are having significant effect on biological activity.Table 5
Observed and predicted antibacterial activity of synthesized 1,3,4-oxadiazole derivatives  againstEscherichia coli and Pseudomonas aeruginosa.
Compounds
Observed  activity
Calculated  activity
Residuals
Observed  activity
Calculated  activity
Residuals
6a
1.39794
1.42696
−0.02902
1.39794
1.380355
0.017585
6b
1.39794
1.49081
−0.09287
—
—
—
6c
—
—
1.69897
1.693166
0.005804
6d
—
—
—
1.69897
1.749717
−0.05075
6e
1.09691
1.17324
−0.07633
—
—
—
6f
—
—
—
1.69897
1.739458
−0.04049
6g
1.39794
1.28492
0.113024
1.69897
1.565732
0.133238
8a
1.09691
1.10285
−0.00594
—
—
—
8b
1.09691
1.22329
−0.12638
—
—
—
8c
1.09691
1.01685
0.080062
—
—
—
8d
2
1.95106
0.048936
2
2.143298
−0.1433
8e
—
—
—
—
—
—
8f
1.69897
1.66784
0.031132
—
—
—
8g
1.09691
1.0879
0.009007
1.39794
1.417768
−0.01983
13a
1.09691
1.2223
−0.12539
1.09691
1.241458
−0.14455
13b
0.79588
0.9957
−0.19982
1.69897
1.59415
0.10482
13d
1.09691
1.13534
−0.03843
1.39794
1.422187
−0.02425
13e
0.79588
0.80956
−0.01368
—
—
—
13f
1.39794
1.03279
0.365149
1.69897
1.642724
0.056246
13h
1.09691
1.11426
−0.01735
2
1.769982
0.230018
(—) Compounds are not included in QSAR model development.


## 4.4. Molecular Docking Studies

Docking studies reported here IN were performed using software Molegro Virtual Docker 5.0.0.The newly synthesized 1,3,4-oxadiazoles derivatives were computationally designed and optimized to investigate the interactions between the target compounds and the amino acid residues of theE. coli PDF.Ni enzyme by molecular docking [15]. Target compounds were docked into active site of PDF (PDB code 1G2A) using MVD (version 5.0.0.) software to observe the affinity for the enzyme and also compared their binding energies with standard drugs such as amoxicillin and cefixime.


## 5. Results and Discussion

### 5.1. Chemistry

The structures of all the newly synthesized derivatives were confirmed by chromatographic and spectroscopic (IR,1H-NMR, 13C NMR, and mass) methods. Both analytical and spectral data of all the synthesized derivatives were in full agreement with the proposed structures. The characteristic C=N band (1680–1520 cm−1) of medium intensity and a medium-strong band at 1300–1050 cm−1 were identified in each IR spectra; the latter could be attributed to the C–O–C vibration or heteroatom ring deformation of the oxadiazole ring. 1H NMR showed characteristic doublets at (7.8–8.2) and 7.0-7.1) due to aromatic protons ofp-methoxy phenyl for derivatives (6a–h). The presence of two methylene groups was confirmed by presence of doublets at (3.0–3.2) and (2.8–3.0). All the other aliphatic and aromatic protons were observed within the expected regions. 13C data also supported the structures of the synthesized derivatives. In the mass spectra, molecular ions of medium intensity and the base peak usually belonged to the corresponding acylium ions and nitrile radical ions, which are formed by the cleavage of heteroatom ring. Both of these have been reported as a characteristic for this family. This part concluded the synthesis of 1,3,4-oxadiazole derivatives.


### 5.2. Antibacterial Activity

The antibacterial activity of the synthesized derivatives was carried out by agar cup plate method and the average radius of zone of inhibition (mm) and MIC (μg/mL) were recorded in comparison with amoxicillin and cefixime. The zone of inhibition of6e (27.82±0.16, 20.63±0.16, 24.6±0.11, and 25.86±0.17 at 400 μg/mL),8h (28.97±0.16, 23.9±0.1, 26.04±0.14, and 26.91±0.19 at 1600 μg/mL),13b (28.95±0.18, 18.11±0.11, 26.16±0.18, and 26.9±0.14 at 200 μg/mL),13c (28.15±0.18, 22.13±0.15, 27.08±0.24, and 28±0.08 at 200 μg/mL), and13e (28.01±0.18, 22.17±0.2, 28.34±0.24, and 28.08±0.07 at 200 μg/mL) was found to be good which is comparable with zone of inhibition of amoxicillin (30±0.1, 13.99±0.23, 18.12±0.12, and 32.06±0.22 at 800 μg/mL) and cefixime (22.18±0.22, 12±0.38, 12.03±0.19, and 20.03±0.15 at 800 μg/mL) indicated that these derivatives have potent antibacterial activity. No inhibitory effect was observed for DMF. All the derivatives were found to be active againstPseudomonas aeruginosa andStaphylococcus aureus. The zone of inhibition and MIC and zone of inhibition of all the synthesized derivatives is summarized in Table 3 (Figure 3) and Table 4 (Figure 4), respectively.An introspection of the active compounds revealed that different structural features of the compounds have more influence on biological activity. Three starting materials which have been selected for design and development of novel substituted 1,3,4-oxadiazole derivatives include methoxy benzene (anisole), N-phenyl anthranilic acid, ando-benzoyl benzoic acid.(i)
All these have a significant influence on increase of lipophilicity, which is responsible for the better activity of the tested compounds, may be due to easy penetration of compounds in the microbial cell membrane. The inclusion of an oxadiazole moiety in the synthesized compounds also showed high lipophilicity, hypothesizing that this lipophilicity could facilitate passage of these compounds through the bacterial membrane. All synthesized compounds have significant logP (octanol-water partition coefficient) which affect drug absorption, distribution, bioavailability, drug-receptor interactions, metabolism, and toxicity profile.(ii)
At one side of 1,3,4-oxadiazole nucleus substitution with phenyl ring or bulkier aromatic groups may also offer significant increase in the biological activity.(iii)
The antimicrobial activity results indicated that the presence of electron-withdrawing halogen groups and nitro group at para and ortho position of the phenyl ring improved their biological activity. On the basis of biological data, improvement in biological activity was observed with an increase in electronegativity of the molecule due to the presence of halogen group(6e, 6f, 8e, 8f, and13b) and nitro group(6h, 8h, 13c, and13g).


### 5.3. QSAR Studies

Multilinear regression is one of the vital method of quantitative structure activity relationship which is used for displaying linear correlation among a dependent variableY (biological activity; MIC50) and independent variable X (physicochemical parameters).


#### 5.3.1. QSAR Model for Antibacterial Activity againstEscherichia coli

Consider the following:(1)pMIC50=-0.03664(LogP)+0.06895(SAS)+0.09532(MR)-44.89(Ovality)-0.06354(MSA)-0.0167(MW)+48.31,(2)N=16,R2=0.831,Radj2=0.718,Press=0.244,Q2=0.8304,F=7.36,S=0.164.Here and hereafter,R2: coefficient of correlation, Radj2: coefficient of determination, F: Fischer statistics, N: numbers of synthesized derivatives, S: standard error of estimate, Press: predictive error sum of squares, Q2: cross validated R2, and BA: biological activity.The observed and predicted antibacterial activity of synthesized 1,3,4-oxadiazole derivatives againstEscherichia coli are summarized in Table 6 and plot of observed and predicted antibacterial activity is given in Figure 5.Table 6
Observed and predicted antibacterial activities of 1,3,4-oxadiazole derivatives againstStaphylococcus aureus and Staphylococcus epidermidis.
Compounds
Staphylococcus aureus
Staphylococcus epidermidis
Observed activity
Calculated activity
Residuals
Observed activity
Calculated activity
Residuals
6a
1.69897
1.747218
−0.04825
2
2.018882
−0.018880
6b
2
2.061071
−0.06107
1.69897
1.726729
−0.027760
6c
2
1.875044
0.124956
1.69897
1.573922
0.125048
6d
2
1.834783
0.165217
—
—
—
6e
1.69897
2.002453
−0.30348
1.69897
1.740717
−0.041750
6f
1.69897
1.827713
−0.12874
—
—
—
6g
1.69897
1.462069
0.236901
—
—
—
8a
—
—
—
—
—
—
8b
1.09691
1.17198
−0.07507
1.69897
1.591267
0.107703
8c
1.09691
1.151688
−0.05478
1.69897
1.732577
−0.033610
8d
2
1.808758
0.191242
1.39794
1.343779
0.054161
8e
2
1.885819
0.114181
1.09691
0.887520
0.209390
8f
1.69897
1.552991
0.145979
1.39794
1.353518
0.044422
8g
1.09691
1.268834
−0.17192
1.39794
1.327929
0.070011
13a
—
—
—
1.39794
1.308439
0.089501
13b
—
—
—
0.79588
1.030457
−0.23458
13d
1.09691
1.056386
0.040524
1.39794
1.425514
−0.02757
13e
—
—
—
1.09691
1.227397
−0.13049
13f
1.39794
1.647697
−0.24976
1.09691
1.118010
−0.02110
13h
1.69897
1.611633
0.087337
1.09691
1.165225
−0.06832
(—) Compounds are not included in QSAR model development.Plot of calculated pMIC50 values against observed pMIC50 for QSAR model for (a)Escherichia coli (b),Pseudomonas aeruginosa (c),Staphylococcus aureus, and (d)Staphylococcus epidermidis.
(a)
(b)
(c)
(d)


#### 5.3.2. QSAR Model for Antibacterial Activity againstPseudomonas aeruginosa

Consider the following:(3)pMIC50=-0.4431(LogP)-0.05285(SAS)-0.01438(MR)-3.004(Ovality)+0.1083(MSA)+0.01097(MW)+2.893,(4)N=12,R2=0.825,Radj2=0.616,Press=0.131,Q2=0.823,F=3.94,S=0.161.The observed and predicted antibacterial activities of synthesized 1,3,4-oxadiazole derivatives againstPseudomonas aeruginosa are summarized in Table 6 and plot of observed and predicted antibacterial activity is given in Figure 5.


#### 5.3.3. QSAR Model for Antibacterial Activity againstStaphylococcus aureus

Consider the following:(5)pMIC50=0.007502(LogP)-0.01653(SAS)-0.0813(MR)-8.436(Ovality)+0.07769(MSA)-0.01452(MW)+13.04,(6)N=16,R2=0.889,Radj2=0.815,Press=0.170,Q2=0.8887,F=12.02,S=0.137.The observed and predicted antibacterial activities of synthesized 1,3,4-oxadiazole derivatives againstStaphylococcus aureus are summarized in Table 7 and plot of observed and predicted antibacterial activities is given in Figure 5.Table 7
Ligand-receptor interaction of synthesized 1,3,4-oxadiazole derivatives with peptide deformylase.
Compound
Docking score (binding energy)
Distance  (Å)
Amino acid
Group involved in interaction with receptor
6e
−77.213
2.63
Lys 150
Oxygen of oxadiazole ring
2.53
Lys 150
Nitrogen of oxadiazole ring
6f
−135.787
2.72
Lys 150
Nitrogen of oxadiazole ring
2.88
Lys 150
Oxygen of oxadiazole ring
8e
−146.825
3.46
Lys 150
Nitrogen of oxadiazole ring
4.27
Lys 150
Nitrogen of oxadiazole ring
8f
−138.439
3.50
Lys 150
Oxygen of oxadiazole ring
3.21
Lys 150
Nitrogen of oxadiazole ring
3.21
Lys 150
Nitrogen of oxadiazole ring
8h
−151.632
3.40
Lys 150
Oxygen of oxadiazole ring
3.41
Lys 150
Nitrogen of oxadiazole ring
3.19
Lys 150
Nitrogen of oxadiazole ring
13b
−88.30
3.19
Arg 97
Oxygen of oxadiazole ring
13c
−96.604
3.31
Lys 150
Nitrogen of oxadiazole ring
3.49
Lys 150
Oxygen of oxadiazole ring
2.69
Arg  97
Nitrogen of nitro group
13e
−153.44
2.95
Lys 157
Oxygen of hydroxyl group
2.02
Arg 153
Oxygen of methoxy group
3.26
Lys 150
Oxygen of oxadiazole ring
13g
−81.702
2.06
Arg 153
Oxygen of nitro group
3.05
Arg 153
Oxygen of oxadiazole ring
Amoxicillin
−128.027
3.54
Arg 153
Oxygen of –COOH group
Cefixime
−153.288
2.76
Lys 150
Nitrogen ofβ-lactam


#### 5.3.4. QSAR Model for Antibacterial Activity againstStaphylococcus epidermidis

Consider the following:(7)pMIC50=-0.2393(LogP)+0.03799(SAS)+0.004048(MR)-6.152(Ovality)-0.07843(MSA)+0.02144(MW)+6.999,(8)N=16,R2=0.796,Radj2=0.654,Press=0.394,Q2=0.792,F=5.74,S=0.209.The observed and predicted antibacterial activities of synthesized 1,3,4-oxadiazole derivatives againstStaphylococcus epidermidis are summarized in Table 7 and plot of observed and predicted antibacterial activities is given in Figure 5.Plot of predicted pMIC50 values against observed pMIC50 for QSAR model of all bacterial strains is given in Figure 5.From the above mentioned QSAR models the following observations can be drawn.(i)
The biological activity has shown dependence on LogP, SAS, MR, ovality, MSA, and MW.(ii)
The aromatic substituents like methoxy benzene(6a–h), N-phenyl anthranilic acid(8a–h), ando-benzoyl benzoic acid(13a–h) in addition to 1,3,4-oxadiazole moiety which resulted in increased lipophilicity leads to better biological activity.(iii)
Also the presence of electron withdrawing group at para and ortho positions in the compounds resulted in enhanced biological activities.(iv)
The results suggested that the antimicrobial activity was highly dependent on LogP, SAS, MR, ovality, MSA, and MW.(v)
The derived models could be used in designing of more potent inhibitors against microbial infections.(vi)
Six parameter correlation equations for antimicrobial activity, having good values of correlation coefficient (r2) and minimum standard error of estimate (S), developed againstE. coli,P. aeruginosa,S. aureus, andS. epidermidis, could be used for the prediction of biological activities of unknown and unavailable compounds of this class.


### 5.4. Molecular Docking Studies

The results of docking study of synthesized 1,3,4-oxadiazole derivatives (Table7) (Figures 6, 7, 8, and 9) with peptide deformylase depicted the hydrogen bonding interactions with Lys 150 (6e,6f,8e,8f,8h,13c, and13e), Lys 157 (13e), Arg 97 (13b and13c), and Arg 153 (13e and13g). The amino acids Lys 150 and Arg 153 were involved in interaction with the standard drugs (cefixime and amoxicillin) as well as the synthesized 1,3,4-oxadiazole derivatives. The docking score of derivatives6f,8e,8f,8h, and13e was found to be higher than amoxicillin and13e was found to have the highest dock scoring derivative than that of amoxicillin and cefixime.Figure 6
Binding modes of6e and6f (6e,6f as docking view and6e′,6f′ as interaction view) with peptide deformylase, where blue/green lines and red lines represent hydrogen bonding and favourable steric interactions, respectively.Figure 7
Binding modes of8e,8f and8h (8e,8f and8h as docking views;8e′,8f′, and8h′ as interaction views) with peptide deformylase, where blue/green lines and red lines represent hydrogen bonding and favourable steric interactions, respectively.Figure 8
Binding modes of13b,13c,13e and13g (13b,13c,13e and13g as docking views;13b′,13c′,13e′ and13g′ as interaction views) with peptide deformylase, where blue/green lines and red lines represent hydrogen bonding and favourable steric interactions, respectively.Figure 9
Binding modes of amoxicillin and cefixime (amoxicillin and cefixime as docking views; amoxicillin’ and cefixime’ as interaction views) with peptide deformylase, where blue/green lines and red lines represent hydrogen bonding and favourable steric interactions, respectively.In synthesized 1,3,4-oxadiazole derivatives replacement of free carboxylic group by oxadiazole nucleus enhanced the receptor interaction by formation of numerous hydrogen bonds and favourable steric interactions with peptide deformylase. These results could be used for the development of novel, potent, and effective antimicrobial agents.The carbonyl, nitro, and 1,3,4-oxadiazole functionalities (acting as acceptor), whereas –NH– and hydroxyl group (acting as donor) in the synthesized derivatives have played very imperative position in ligand-receptor interaction for the creation of numerous hydrogen bonds. Insertion of electron withdrawing 1,3,4-oxadiazole offers an upgradedπ-electron delocalization across the donor-acceptor links and affords significant electron transportation. Results also revealed that the hydrogen bond distance is important in docking studies. The distance more than 3.2 Å indicates feeble hydrogen bonding between ligand and receptor, 2.6 Å–3.2 Å represents virtuous hydrogen bonding, and less than 2.5 Å indicates robust bonding. Almost all the active derivatives showed good hydrogen bonding with enzymes.


## 5.1. Chemistry

The structures of all the newly synthesized derivatives were confirmed by chromatographic and spectroscopic (IR,1H-NMR, 13C NMR, and mass) methods. Both analytical and spectral data of all the synthesized derivatives were in full agreement with the proposed structures. The characteristic C=N band (1680–1520 cm−1) of medium intensity and a medium-strong band at 1300–1050 cm−1 were identified in each IR spectra; the latter could be attributed to the C–O–C vibration or heteroatom ring deformation of the oxadiazole ring. 1H NMR showed characteristic doublets at (7.8–8.2) and 7.0-7.1) due to aromatic protons ofp-methoxy phenyl for derivatives (6a–h). The presence of two methylene groups was confirmed by presence of doublets at (3.0–3.2) and (2.8–3.0). All the other aliphatic and aromatic protons were observed within the expected regions. 13C data also supported the structures of the synthesized derivatives. In the mass spectra, molecular ions of medium intensity and the base peak usually belonged to the corresponding acylium ions and nitrile radical ions, which are formed by the cleavage of heteroatom ring. Both of these have been reported as a characteristic for this family. This part concluded the synthesis of 1,3,4-oxadiazole derivatives.


## 5.2. Antibacterial Activity

The antibacterial activity of the synthesized derivatives was carried out by agar cup plate method and the average radius of zone of inhibition (mm) and MIC (μg/mL) were recorded in comparison with amoxicillin and cefixime. The zone of inhibition of6e (27.82±0.16, 20.63±0.16, 24.6±0.11, and 25.86±0.17 at 400 μg/mL),8h (28.97±0.16, 23.9±0.1, 26.04±0.14, and 26.91±0.19 at 1600 μg/mL),13b (28.95±0.18, 18.11±0.11, 26.16±0.18, and 26.9±0.14 at 200 μg/mL),13c (28.15±0.18, 22.13±0.15, 27.08±0.24, and 28±0.08 at 200 μg/mL), and13e (28.01±0.18, 22.17±0.2, 28.34±0.24, and 28.08±0.07 at 200 μg/mL) was found to be good which is comparable with zone of inhibition of amoxicillin (30±0.1, 13.99±0.23, 18.12±0.12, and 32.06±0.22 at 800 μg/mL) and cefixime (22.18±0.22, 12±0.38, 12.03±0.19, and 20.03±0.15 at 800 μg/mL) indicated that these derivatives have potent antibacterial activity. No inhibitory effect was observed for DMF. All the derivatives were found to be active againstPseudomonas aeruginosa andStaphylococcus aureus. The zone of inhibition and MIC and zone of inhibition of all the synthesized derivatives is summarized in Table 3 (Figure 3) and Table 4 (Figure 4), respectively.An introspection of the active compounds revealed that different structural features of the compounds have more influence on biological activity. Three starting materials which have been selected for design and development of novel substituted 1,3,4-oxadiazole derivatives include methoxy benzene (anisole), N-phenyl anthranilic acid, ando-benzoyl benzoic acid.(i)
All these have a significant influence on increase of lipophilicity, which is responsible for the better activity of the tested compounds, may be due to easy penetration of compounds in the microbial cell membrane. The inclusion of an oxadiazole moiety in the synthesized compounds also showed high lipophilicity, hypothesizing that this lipophilicity could facilitate passage of these compounds through the bacterial membrane. All synthesized compounds have significant logP (octanol-water partition coefficient) which affect drug absorption, distribution, bioavailability, drug-receptor interactions, metabolism, and toxicity profile.(ii)
At one side of 1,3,4-oxadiazole nucleus substitution with phenyl ring or bulkier aromatic groups may also offer significant increase in the biological activity.(iii)
The antimicrobial activity results indicated that the presence of electron-withdrawing halogen groups and nitro group at para and ortho position of the phenyl ring improved their biological activity. On the basis of biological data, improvement in biological activity was observed with an increase in electronegativity of the molecule due to the presence of halogen group(6e, 6f, 8e, 8f, and13b) and nitro group(6h, 8h, 13c, and13g).


## 5.3. QSAR Studies

Multilinear regression is one of the vital method of quantitative structure activity relationship which is used for displaying linear correlation among a dependent variableY (biological activity; MIC50) and independent variable X (physicochemical parameters).


### 5.3.1. QSAR Model for Antibacterial Activity againstEscherichia coli

Consider the following:(1)pMIC50=-0.03664(LogP)+0.06895(SAS)+0.09532(MR)-44.89(Ovality)-0.06354(MSA)-0.0167(MW)+48.31,(2)N=16,R2=0.831,Radj2=0.718,Press=0.244,Q2=0.8304,F=7.36,S=0.164.Here and hereafter,R2: coefficient of correlation, Radj2: coefficient of determination, F: Fischer statistics, N: numbers of synthesized derivatives, S: standard error of estimate, Press: predictive error sum of squares, Q2: cross validated R2, and BA: biological activity.The observed and predicted antibacterial activity of synthesized 1,3,4-oxadiazole derivatives againstEscherichia coli are summarized in Table 6 and plot of observed and predicted antibacterial activity is given in Figure 5.Table 6
Observed and predicted antibacterial activities of 1,3,4-oxadiazole derivatives againstStaphylococcus aureus and Staphylococcus epidermidis.
Compounds
Staphylococcus aureus
Staphylococcus epidermidis
Observed activity
Calculated activity
Residuals
Observed activity
Calculated activity
Residuals
6a
1.69897
1.747218
−0.04825
2
2.018882
−0.018880
6b
2
2.061071
−0.06107
1.69897
1.726729
−0.027760
6c
2
1.875044
0.124956
1.69897
1.573922
0.125048
6d
2
1.834783
0.165217
—
—
—
6e
1.69897
2.002453
−0.30348
1.69897
1.740717
−0.041750
6f
1.69897
1.827713
−0.12874
—
—
—
6g
1.69897
1.462069
0.236901
—
—
—
8a
—
—
—
—
—
—
8b
1.09691
1.17198
−0.07507
1.69897
1.591267
0.107703
8c
1.09691
1.151688
−0.05478
1.69897
1.732577
−0.033610
8d
2
1.808758
0.191242
1.39794
1.343779
0.054161
8e
2
1.885819
0.114181
1.09691
0.887520
0.209390
8f
1.69897
1.552991
0.145979
1.39794
1.353518
0.044422
8g
1.09691
1.268834
−0.17192
1.39794
1.327929
0.070011
13a
—
—
—
1.39794
1.308439
0.089501
13b
—
—
—
0.79588
1.030457
−0.23458
13d
1.09691
1.056386
0.040524
1.39794
1.425514
−0.02757
13e
—
—
—
1.09691
1.227397
−0.13049
13f
1.39794
1.647697
−0.24976
1.09691
1.118010
−0.02110
13h
1.69897
1.611633
0.087337
1.09691
1.165225
−0.06832
(—) Compounds are not included in QSAR model development.Plot of calculated pMIC50 values against observed pMIC50 for QSAR model for (a)Escherichia coli (b),Pseudomonas aeruginosa (c),Staphylococcus aureus, and (d)Staphylococcus epidermidis.
(a)
(b)
(c)
(d)


### 5.3.2. QSAR Model for Antibacterial Activity againstPseudomonas aeruginosa

Consider the following:(3)pMIC50=-0.4431(LogP)-0.05285(SAS)-0.01438(MR)-3.004(Ovality)+0.1083(MSA)+0.01097(MW)+2.893,(4)N=12,R2=0.825,Radj2=0.616,Press=0.131,Q2=0.823,F=3.94,S=0.161.The observed and predicted antibacterial activities of synthesized 1,3,4-oxadiazole derivatives againstPseudomonas aeruginosa are summarized in Table 6 and plot of observed and predicted antibacterial activity is given in Figure 5.


### 5.3.3. QSAR Model for Antibacterial Activity againstStaphylococcus aureus

Consider the following:(5)pMIC50=0.007502(LogP)-0.01653(SAS)-0.0813(MR)-8.436(Ovality)+0.07769(MSA)-0.01452(MW)+13.04,(6)N=16,R2=0.889,Radj2=0.815,Press=0.170,Q2=0.8887,F=12.02,S=0.137.The observed and predicted antibacterial activities of synthesized 1,3,4-oxadiazole derivatives againstStaphylococcus aureus are summarized in Table 7 and plot of observed and predicted antibacterial activities is given in Figure 5.Table 7
Ligand-receptor interaction of synthesized 1,3,4-oxadiazole derivatives with peptide deformylase.
Compound
Docking score (binding energy)
Distance  (Å)
Amino acid
Group involved in interaction with receptor
6e
−77.213
2.63
Lys 150
Oxygen of oxadiazole ring
2.53
Lys 150
Nitrogen of oxadiazole ring
6f
−135.787
2.72
Lys 150
Nitrogen of oxadiazole ring
2.88
Lys 150
Oxygen of oxadiazole ring
8e
−146.825
3.46
Lys 150
Nitrogen of oxadiazole ring
4.27
Lys 150
Nitrogen of oxadiazole ring
8f
−138.439
3.50
Lys 150
Oxygen of oxadiazole ring
3.21
Lys 150
Nitrogen of oxadiazole ring
3.21
Lys 150
Nitrogen of oxadiazole ring
8h
−151.632
3.40
Lys 150
Oxygen of oxadiazole ring
3.41
Lys 150
Nitrogen of oxadiazole ring
3.19
Lys 150
Nitrogen of oxadiazole ring
13b
−88.30
3.19
Arg 97
Oxygen of oxadiazole ring
13c
−96.604
3.31
Lys 150
Nitrogen of oxadiazole ring
3.49
Lys 150
Oxygen of oxadiazole ring
2.69
Arg  97
Nitrogen of nitro group
13e
−153.44
2.95
Lys 157
Oxygen of hydroxyl group
2.02
Arg 153
Oxygen of methoxy group
3.26
Lys 150
Oxygen of oxadiazole ring
13g
−81.702
2.06
Arg 153
Oxygen of nitro group
3.05
Arg 153
Oxygen of oxadiazole ring
Amoxicillin
−128.027
3.54
Arg 153
Oxygen of –COOH group
Cefixime
−153.288
2.76
Lys 150
Nitrogen ofβ-lactam


### 5.3.4. QSAR Model for Antibacterial Activity againstStaphylococcus epidermidis

Consider the following:(7)pMIC50=-0.2393(LogP)+0.03799(SAS)+0.004048(MR)-6.152(Ovality)-0.07843(MSA)+0.02144(MW)+6.999,(8)N=16,R2=0.796,Radj2=0.654,Press=0.394,Q2=0.792,F=5.74,S=0.209.The observed and predicted antibacterial activities of synthesized 1,3,4-oxadiazole derivatives againstStaphylococcus epidermidis are summarized in Table 7 and plot of observed and predicted antibacterial activities is given in Figure 5.Plot of predicted pMIC50 values against observed pMIC50 for QSAR model of all bacterial strains is given in Figure 5.From the above mentioned QSAR models the following observations can be drawn.(i)
The biological activity has shown dependence on LogP, SAS, MR, ovality, MSA, and MW.(ii)
The aromatic substituents like methoxy benzene(6a–h), N-phenyl anthranilic acid(8a–h), ando-benzoyl benzoic acid(13a–h) in addition to 1,3,4-oxadiazole moiety which resulted in increased lipophilicity leads to better biological activity.(iii)
Also the presence of electron withdrawing group at para and ortho positions in the compounds resulted in enhanced biological activities.(iv)
The results suggested that the antimicrobial activity was highly dependent on LogP, SAS, MR, ovality, MSA, and MW.(v)
The derived models could be used in designing of more potent inhibitors against microbial infections.(vi)
Six parameter correlation equations for antimicrobial activity, having good values of correlation coefficient (r2) and minimum standard error of estimate (S), developed againstE. coli,P. aeruginosa,S. aureus, andS. epidermidis, could be used for the prediction of biological activities of unknown and unavailable compounds of this class.


## 5.3.1. QSAR Model for Antibacterial Activity againstEscherichia coli

Consider the following:(1)pMIC50=-0.03664(LogP)+0.06895(SAS)+0.09532(MR)-44.89(Ovality)-0.06354(MSA)-0.0167(MW)+48.31,(2)N=16,R2=0.831,Radj2=0.718,Press=0.244,Q2=0.8304,F=7.36,S=0.164.Here and hereafter,R2: coefficient of correlation, Radj2: coefficient of determination, F: Fischer statistics, N: numbers of synthesized derivatives, S: standard error of estimate, Press: predictive error sum of squares, Q2: cross validated R2, and BA: biological activity.The observed and predicted antibacterial activity of synthesized 1,3,4-oxadiazole derivatives againstEscherichia coli are summarized in Table 6 and plot of observed and predicted antibacterial activity is given in Figure 5.Table 6
Observed and predicted antibacterial activities of 1,3,4-oxadiazole derivatives againstStaphylococcus aureus and Staphylococcus epidermidis.
Compounds
Staphylococcus aureus
Staphylococcus epidermidis
Observed activity
Calculated activity
Residuals
Observed activity
Calculated activity
Residuals
6a
1.69897
1.747218
−0.04825
2
2.018882
−0.018880
6b
2
2.061071
−0.06107
1.69897
1.726729
−0.027760
6c
2
1.875044
0.124956
1.69897
1.573922
0.125048
6d
2
1.834783
0.165217
—
—
—
6e
1.69897
2.002453
−0.30348
1.69897
1.740717
−0.041750
6f
1.69897
1.827713
−0.12874
—
—
—
6g
1.69897
1.462069
0.236901
—
—
—
8a
—
—
—
—
—
—
8b
1.09691
1.17198
−0.07507
1.69897
1.591267
0.107703
8c
1.09691
1.151688
−0.05478
1.69897
1.732577
−0.033610
8d
2
1.808758
0.191242
1.39794
1.343779
0.054161
8e
2
1.885819
0.114181
1.09691
0.887520
0.209390
8f
1.69897
1.552991
0.145979
1.39794
1.353518
0.044422
8g
1.09691
1.268834
−0.17192
1.39794
1.327929
0.070011
13a
—
—
—
1.39794
1.308439
0.089501
13b
—
—
—
0.79588
1.030457
−0.23458
13d
1.09691
1.056386
0.040524
1.39794
1.425514
−0.02757
13e
—
—
—
1.09691
1.227397
−0.13049
13f
1.39794
1.647697
−0.24976
1.09691
1.118010
−0.02110
13h
1.69897
1.611633
0.087337
1.09691
1.165225
−0.06832
(—) Compounds are not included in QSAR model development.Plot of calculated pMIC50 values against observed pMIC50 for QSAR model for (a)Escherichia coli (b),Pseudomonas aeruginosa (c),Staphylococcus aureus, and (d)Staphylococcus epidermidis.
(a)
(b)
(c)
(d)


## 5.3.2. QSAR Model for Antibacterial Activity againstPseudomonas aeruginosa

Consider the following:(3)pMIC50=-0.4431(LogP)-0.05285(SAS)-0.01438(MR)-3.004(Ovality)+0.1083(MSA)+0.01097(MW)+2.893,(4)N=12,R2=0.825,Radj2=0.616,Press=0.131,Q2=0.823,F=3.94,S=0.161.The observed and predicted antibacterial activities of synthesized 1,3,4-oxadiazole derivatives againstPseudomonas aeruginosa are summarized in Table 6 and plot of observed and predicted antibacterial activity is given in Figure 5.


## 5.3.3. QSAR Model for Antibacterial Activity againstStaphylococcus aureus

Consider the following:(5)pMIC50=0.007502(LogP)-0.01653(SAS)-0.0813(MR)-8.436(Ovality)+0.07769(MSA)-0.01452(MW)+13.04,(6)N=16,R2=0.889,Radj2=0.815,Press=0.170,Q2=0.8887,F=12.02,S=0.137.The observed and predicted antibacterial activities of synthesized 1,3,4-oxadiazole derivatives againstStaphylococcus aureus are summarized in Table 7 and plot of observed and predicted antibacterial activities is given in Figure 5.Table 7
Ligand-receptor interaction of synthesized 1,3,4-oxadiazole derivatives with peptide deformylase.
Compound
Docking score (binding energy)
Distance  (Å)
Amino acid
Group involved in interaction with receptor
6e
−77.213
2.63
Lys 150
Oxygen of oxadiazole ring
2.53
Lys 150
Nitrogen of oxadiazole ring
6f
−135.787
2.72
Lys 150
Nitrogen of oxadiazole ring
2.88
Lys 150
Oxygen of oxadiazole ring
8e
−146.825
3.46
Lys 150
Nitrogen of oxadiazole ring
4.27
Lys 150
Nitrogen of oxadiazole ring
8f
−138.439
3.50
Lys 150
Oxygen of oxadiazole ring
3.21
Lys 150
Nitrogen of oxadiazole ring
3.21
Lys 150
Nitrogen of oxadiazole ring
8h
−151.632
3.40
Lys 150
Oxygen of oxadiazole ring
3.41
Lys 150
Nitrogen of oxadiazole ring
3.19
Lys 150
Nitrogen of oxadiazole ring
13b
−88.30
3.19
Arg 97
Oxygen of oxadiazole ring
13c
−96.604
3.31
Lys 150
Nitrogen of oxadiazole ring
3.49
Lys 150
Oxygen of oxadiazole ring
2.69
Arg  97
Nitrogen of nitro group
13e
−153.44
2.95
Lys 157
Oxygen of hydroxyl group
2.02
Arg 153
Oxygen of methoxy group
3.26
Lys 150
Oxygen of oxadiazole ring
13g
−81.702
2.06
Arg 153
Oxygen of nitro group
3.05
Arg 153
Oxygen of oxadiazole ring
Amoxicillin
−128.027
3.54
Arg 153
Oxygen of –COOH group
Cefixime
−153.288
2.76
Lys 150
Nitrogen ofβ-lactam


## 5.3.4. QSAR Model for Antibacterial Activity againstStaphylococcus epidermidis

Consider the following:(7)pMIC50=-0.2393(LogP)+0.03799(SAS)+0.004048(MR)-6.152(Ovality)-0.07843(MSA)+0.02144(MW)+6.999,(8)N=16,R2=0.796,Radj2=0.654,Press=0.394,Q2=0.792,F=5.74,S=0.209.The observed and predicted antibacterial activities of synthesized 1,3,4-oxadiazole derivatives againstStaphylococcus epidermidis are summarized in Table 7 and plot of observed and predicted antibacterial activities is given in Figure 5.Plot of predicted pMIC50 values against observed pMIC50 for QSAR model of all bacterial strains is given in Figure 5.From the above mentioned QSAR models the following observations can be drawn.(i)
The biological activity has shown dependence on LogP, SAS, MR, ovality, MSA, and MW.(ii)
The aromatic substituents like methoxy benzene(6a–h), N-phenyl anthranilic acid(8a–h), ando-benzoyl benzoic acid(13a–h) in addition to 1,3,4-oxadiazole moiety which resulted in increased lipophilicity leads to better biological activity.(iii)
Also the presence of electron withdrawing group at para and ortho positions in the compounds resulted in enhanced biological activities.(iv)
The results suggested that the antimicrobial activity was highly dependent on LogP, SAS, MR, ovality, MSA, and MW.(v)
The derived models could be used in designing of more potent inhibitors against microbial infections.(vi)
Six parameter correlation equations for antimicrobial activity, having good values of correlation coefficient (r2) and minimum standard error of estimate (S), developed againstE. coli,P. aeruginosa,S. aureus, andS. epidermidis, could be used for the prediction of biological activities of unknown and unavailable compounds of this class.


## 5.4. Molecular Docking Studies

The results of docking study of synthesized 1,3,4-oxadiazole derivatives (Table7) (Figures 6, 7, 8, and 9) with peptide deformylase depicted the hydrogen bonding interactions with Lys 150 (6e,6f,8e,8f,8h,13c, and13e), Lys 157 (13e), Arg 97 (13b and13c), and Arg 153 (13e and13g). The amino acids Lys 150 and Arg 153 were involved in interaction with the standard drugs (cefixime and amoxicillin) as well as the synthesized 1,3,4-oxadiazole derivatives. The docking score of derivatives6f,8e,8f,8h, and13e was found to be higher than amoxicillin and13e was found to have the highest dock scoring derivative than that of amoxicillin and cefixime.Figure 6
Binding modes of6e and6f (6e,6f as docking view and6e′,6f′ as interaction view) with peptide deformylase, where blue/green lines and red lines represent hydrogen bonding and favourable steric interactions, respectively.Figure 7
Binding modes of8e,8f and8h (8e,8f and8h as docking views;8e′,8f′, and8h′ as interaction views) with peptide deformylase, where blue/green lines and red lines represent hydrogen bonding and favourable steric interactions, respectively.Figure 8
Binding modes of13b,13c,13e and13g (13b,13c,13e and13g as docking views;13b′,13c′,13e′ and13g′ as interaction views) with peptide deformylase, where blue/green lines and red lines represent hydrogen bonding and favourable steric interactions, respectively.Figure 9
Binding modes of amoxicillin and cefixime (amoxicillin and cefixime as docking views; amoxicillin’ and cefixime’ as interaction views) with peptide deformylase, where blue/green lines and red lines represent hydrogen bonding and favourable steric interactions, respectively.In synthesized 1,3,4-oxadiazole derivatives replacement of free carboxylic group by oxadiazole nucleus enhanced the receptor interaction by formation of numerous hydrogen bonds and favourable steric interactions with peptide deformylase. These results could be used for the development of novel, potent, and effective antimicrobial agents.The carbonyl, nitro, and 1,3,4-oxadiazole functionalities (acting as acceptor), whereas –NH– and hydroxyl group (acting as donor) in the synthesized derivatives have played very imperative position in ligand-receptor interaction for the creation of numerous hydrogen bonds. Insertion of electron withdrawing 1,3,4-oxadiazole offers an upgradedπ-electron delocalization across the donor-acceptor links and affords significant electron transportation. Results also revealed that the hydrogen bond distance is important in docking studies. The distance more than 3.2 Å indicates feeble hydrogen bonding between ligand and receptor, 2.6 Å–3.2 Å represents virtuous hydrogen bonding, and less than 2.5 Å indicates robust bonding. Almost all the active derivatives showed good hydrogen bonding with enzymes.


## 6. Conclusion

Among all the synthesized derivatives6e,6f,13b,86,8f,8h 13c, and13e were observed as the best antibacterial agents against all the selected microbial strains. While studying MIC against bacterial strains, compound13b withp-chloro and13e withm-methoxy andp-hydroxyl substitutions were found to be the most active among all the derivatives. In developed QSAR models, six physicochemical parameters (LogP, SAS, MR, ovality, MSA, and MW) were instituted to be important for the antibacterial activity. All the developed models have good coefficient of correlation (0.796–0.885), coefficient of determination (0.616–0.815), and cross validated R2 (0.792–0.888) with good Fischer statistics (3.94–12.02). Among all the synthesized compounds13e was found to be most potent peptide deformylase inhibitor with the highest dock score (−153.44) than that of amoxicillin and cefixime.



---

*Source: 172791-2014-07-24.xml*